[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 130
1. Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, Lichter P, Bentz M, Döhner H, Möller P, Schwaenen C: Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia; 2007 Dec;21(12):2463-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH).
  • Primary mediastinal B-cell lymphoma (PMBL) is an aggressive extranodal B-cell non-Hodgkin's lymphoma with specific clinical, histopathological and genomic features.
  • To characterize further the genotype of PMBL, we analyzed 37 tumor samples and PMBL cell lines Med-B1 and Karpas1106P using array-based comparative genomic hybridization (matrix- or array-CGH) to a 2.8k genomic microarray.
  • [MeSH-major] Chromosome Aberrations. Consensus Sequence. Gene Expression Profiling / methods. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics
  • [MeSH-minor] Adult. Apoptosis / genetics. Cell Line, Tumor / metabolism. Chromosome Deletion. Female. Gene Amplification. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Janus Kinases / genetics. Janus Kinases / metabolism. Male. Middle Aged. NF-kappa B / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. STAT Transcription Factors / genetics. STAT Transcription Factors / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728785.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / STAT Transcription Factors; EC 2.7.10.2 / Janus Kinases
  •  go-up   go-down


2. Weniger MA, Pulford K, Gesk S, Ehrlich S, Banham AH, Lyne L, Martin-Subero JI, Siebert R, Dyer MJ, Möller P, Barth TF: Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia; 2006 Oct;20(10):1880-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.
  • [MeSH-major] Carrier Proteins / genetics. Carrier Proteins / metabolism. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics. Nuclear Proteins / genetics. Nuclear Proteins / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871282.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL11A protein, human; 0 / Carrier Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


3. Rodríguez J, Gutiérrez A, Piris M: Primary mediastinal B-cell lymphoma: treatment and therapeutic targets. Leuk Lymphoma; 2008 Jun;49(6):1050-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal B-cell lymphoma: treatment and therapeutic targets.
  • Primary mediastinal B-cell lymphoma (PMBCL) is a recognised subtype of diffuse large B-cell lymphoma according to the WHO classification that represents approximately 5% of aggressive lymphomas, and 2% of all cases of lymphomas.
  • It presents with unique clinical, morphologic and immunophenotypic characteristics that define the disease.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Mediastinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452109.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 78
  •  go-up   go-down


Advertisement
4. Matsui N, Akahoshi K, Motomura Y, Kubokawa M, Endoh S, Matsuura R, Oda H, Nakashima Y, Oya M, Nakamura K: Successful endoscopic ultrasound-guided fine-needle aspiration of the pelvic lesion through the sigmoid colon. Dig Endosc; 2010 Oct;22(4):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful modality when the target is a lymph node located in the mediastinum, perigastric area or perirectum.
  • Although it is difficult to carry out EUS-FNA of the colon using an oblique view linear scope, we report two cases of successful EUS-FNA of the lesions via the proximal sigmoid colon using a recently available new convex type EUS scope.
  • Case 2 was a 60-year-old Japanese woman noted to have a large mass in the left lower abdomen.
  • In both cases, EUS with forward-viewing radial echoendoscope was carried out via the anus, and multiple lymph-node swelling or a large mass was observed near the proximal sigmoid colon.
  • In the EUS-FNA for these cases, we used a new convex-type EUS scope that has an oblique view, but with a wide-angled optical device giving a view similar to a forward one.
  • The pathological specimen revealed diffuse large B-cell lymphoma in case 1 and gastrointestinal stromal tumor (GIST) in case 2.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Gastrointestinal Stromal Tumors / pathology. Lymphoma, B-Cell / pathology. Sigmoid Neoplasms / pathology. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Digestive Endoscopy © 2010 Japan Gastroenterological Endoscopy Society.
  • (PMID = 21175492.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


5. Eberle FC, Mani H, Jaffe ES: Histopathology of Hodgkin's lymphoma. Cancer J; 2009 Mar-Apr;15(2):129-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology of Hodgkin's lymphoma.
  • In the last few years, there has been a greater understanding of the spectrum and biology of Hodgkin's lymphoma.
  • In standard texts, Hodgkin's lymphoma is classified as 2 distinct entities, namely nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.
  • However, recent evidence suggests that classical Hodgkin's lymphoma is not a single disease.
  • Although the mixed cellularity and lymphocyte-depleted subtypes may be part of a biologic continuum, the nodular sclerosis subtype has a distinct epidemiology, clinical presentation, and histology.
  • Nodular sclerosis Hodgkin's lymphoma, particularly those cases presenting with mediastinal disease, also seems related to primary mediastinal B-cell lymphoma.
  • As Hodgkin's lymphoma is a B-cell neoplasm, there is also a better appreciation today of cases that may be borderline with conventional B-cell lymphomas.
  • We present an update on the histopathological features of Hodgkin's lymphoma and the immunohistochemical tools available for diagnosis in the clinical setting.
  • [MeSH-minor] History, 19th Century. History, 20th Century. Humans. Immunohistochemistry. Lymphocytes / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / history. Lymphoma, B-Cell / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390308.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 118
  •  go-up   go-down


6. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA: NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood; 2005 Aug 15;106(4):1392-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
  • Primary mediastinal large B-cell lymphoma (MLBCL) shares important clinical and molecular features with classic Hodgkin lymphoma, including nuclear localization of the nuclear factor kappaB (NFkappaB) subunit c-REL (reticuloendotheliosis viral oncogene homolog) in a pilot series.
  • Herein, we analyzed c-REL subcellular localization in additional primary MLBCLs and characterized NFkappaB activity and function in a MLBCL cell line.
  • The new primary MLBCLs had prominent c-REL nuclear staining, and the MLBCL cell line exhibited high levels of NFkappaB binding activity.
  • MLBCL cells expressing a superrepressor form of inhibitor of kappa B alpha signaling (IkappaB alpha) had a markedly higher rate of apoptosis, implicating constitutive NFkappaB activity in MLBCL cell survival.
  • The transcriptional profiles of newly diagnosed primary MLBCLs and diffuse large B-cell lymphomas (DLBCLs) were then used to characterize the NFkappaB target gene signatures of MLBCL and specific DLBCL subtypes.
  • MLBCLs expressed increased levels of NFkappaB targets that promote cell survival and favor antiapoptotic tumor necrosis factor alpha (TNFalpha) signaling.
  • In contrast, activated B cell (ABC)-like DLBCLs had a more restricted, potentially developmentally regulated, NFkappaB target gene signature.
  • Of interest, the newly characterized host response DLBCL subtype had a robust NFkappaB target gene signature that partially overlapped that of primary MLBCL.
  • In this large series of primary MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. NF-kappa B / physiology. Proto-Oncogene Proteins c-rel / genetics
  • [MeSH-minor] Apoptosis. Cell Line, Tumor. Gene Expression Profiling. Humans

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870177.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel
  •  go-up   go-down


7. Miles RR, Mankey CC, Seiler CE 3rd, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS, Lim MS: Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol; 2009 Dec;40(12):1731-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
  • Growth factor receptor-bound protein 2 is an adaptor molecule that mediates B-cell receptor (BCR) signaling pathways, but the expression of growth factor receptor-bound protein 2 in lymphoma tissues has not been reported.
  • We sought to characterize growth factor receptor-bound protein 2 protein expression in reactive tonsillar tissues and lymphoma tissues obtained from diagnostic biopsies of classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, diffuse large B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, and 20 low-grade B-cell lymphomas.
  • Growth factor receptor-bound protein 2 expression was assessed in tissues by immunohistochemistry and in lymphoma cell lines by immunoblotting.
  • In reactive lymphoid tissues, growth factor receptor-bound protein 2 was expressed in the cytoplasm of B-cells and histiocytes but not T-cells.
  • Strong, cytoplasmic growth factor receptor-bound protein 2 expression was seen in the neoplastic cells of follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, splenic marginal zone lymphoma, primary mediastinal large B-cell lymphoma, diffuse large B-cell lymphoma, and nodular lymphocyte predominant Hodgkin lymphoma.
  • In contrast, only 10% of the classical Hodgkin lymphomas showed growth factor receptor-bound protein 2 expression in the neoplastic cells.
  • Growth factor receptor-bound protein 2 protein expression was detected by Western blotting in all lymphoma cell lines tested with higher levels in primary mediastinal large B-cell lymphoma compared with classical Hodgkin lymphoma cell lines.
  • These findings support a role for growth factor receptor-bound protein 2 in the diagnostically challenging workup of classical Hodgkin lymphoma versus primary mediastinal large B-cell lymphoma and warrant further studies to evaluate the biologic significance of growth factor receptor-bound protein 2 in the pathogenesis of classical Hodgkin lymphoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. GRB2 Adaptor Protein / biosynthesis. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Blotting, Western. Diagnosis, Differential. Humans. Immunohistochemistry. Tissue Array Analysis


8. Andriamparany J, Margery J, Grand B, Saint-Blancard P: [Primary mediastinal large B-cell lymphoma: histopathologic features. A specific tumour]. Rev Pneumol Clin; 2010 Jun;66(3):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal large B-cell lymphoma: histopathologic features. A specific tumour].
  • [Transliterated title] Le lymphome B à grandes cellules primitif du mediastin, une tumeur particulière. Aspects anatomopathologiques.
  • The diffuse large B-cell lymphomas of the mediastinum were long considered to be a variant of the classic forms of large B-cell lymphomas.
  • However, their clinical and radiological features and especially their histopathological variants point to other lymphoid tumours such as Hodgkin's disease or anaplastic lymphomas, thymic tumours, germ cell tumours or metastatic tumors.
  • The immunohistochemical findings are of prime importance in the diagnosis.
  • Currently, they represent a distinct entity among the large B-cell lymphomas, due to their clinical, pathological and molecular features as well as the outcome.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20561485.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Dunphy CH, O'Malley DP, Cheng L, Fodrie TY, Perkins SL, Kaiser-Rogers K: Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH. J Hematop; 2008 Sep;1(2):77-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal B-cell lymphoma: detection of BCL2 gene rearrangements by PCR analysis and FISH.
  • Primary mediastinal large B-cell lymphoma (PMBCL) has a characteristic clinical presentation, morphology, and immunophenotype, representing a clinically favorable subgroup of diffuse large B-cell lymphoma (DLBCL).
  • By gene expression profiling (GEP), PMBCL shares features with classical Hodgkin lymphoma (cHL).
  • Of further interest, BCL6 gene mutations and BCL6 and/or MUM1 expression in a number of PMBCLs have supported an activated B-cell (ABC) origin.
  • Of the five with cytogenetics, two had a t(14;.
  • BCL2 protein expression by IHC analysis was variably detected in 21 out of 24 (strongly, uniformly expressed: 6, including all with a t(14;.
  • 18) or a BCL2 gene rearrangement; moderately weakly expressed in a subset of the malignant cells: 15).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Oct;107(1):106-13 [10520030.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):748-56 [6784911.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S21-6 [15202521.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Feb;33(2):114-22 [11793437.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):47-53 [11342356.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jun;31(2):191-5 [11319807.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2017-25 [8669486.001]
  • (PMID = 19669206.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713480
  •  go-up   go-down


10. Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S, Italian Society of Hematology, Italian Society of Experimental Hematology, Italian Group for Bone Marrow Transplantation: Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica; 2008 Sep;93(9):1364-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
  • Extranodal non-Hodgkin's lymphomas constitute 20-25% of overall non-Hodgkin's lymphomas cases and can be managed with very different therapeutic strategies.
  • Primary lung and mediastinal lymphomas were the objective of this part of the project.
  • The first-line therapy for non-MALT primary lung non-Hodgkin's lymphomas should include anthracycline-based chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D).
  • Second-line therapy with high-dose chemotherapy and autologous stem cell transplantation is recommended (grade B).
  • In patients with MALT primary lung non-Hodgkin's lymphomas, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B).
  • For treatment of primary mediastinal large B-cell lymphomas, the recommended first-line therapy is a chemotherapy and radiotherapy association (grade B).
  • Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treatment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem cell transplantation (grade B).
  • [MeSH-major] Bone Marrow Transplantation. Lung Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Mediastinal Neoplasms / therapy. Practice Guidelines as Topic / standards


11. Ortonne N, Copie-Bergman C, Remy P, Delfau-Larue MH, Alonso MA, Mariette X, Dierlamm J, Leroy K, Gaulard P: Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. Virchows Arch; 2005 Feb;446(2):189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement.
  • We report a case of thymic mucosa-associated lymphoid tissue (MALT) lymphoma (TML) that presented as an asymptomatic mediastinal mass in a 40-year-old woman with a past history of Sjögren syndrome.
  • This case had the characteristic clinical and pathological features of TML, as found in most of the 24 previously reported cases, i.e., autoimmune context, especially Sjögren syndrome, IgA secretion, large epithelial cysts, lymphoepithelial lesions involving residual Hassal's corpuscles, epithelial cysts, and a marked plasmacytic differentiation with IgA expression.
  • Neoplastic cells were negative for MAL, a marker of primary mediastinal large B cell lymphoma (PMBL).
  • Altogether, these findings further support that among MALT lymphomas, TML have peculiar clinical and morphological characteristics and appear not to involve MALT1 rearrangement.
  • They also suggest the absence of a relationship between TML and PMBL.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasm Proteins / genetics. Thymus Neoplasms / genetics. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1993 Dec;9(6):665-7 [8143541.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1347-55 [1540872.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):255-9 [10685645.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):1021-4 [9744322.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):74-81 [9589469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1435-43 [11943727.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2335-9 [12406890.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):51-6 [11789730.001]
  • [Cites] Jpn J Clin Oncol. 2000 Aug;30(8):349-53 [11059340.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):595-7 [8813963.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3567-75 [10552968.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):770-3 [10782167.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):342-51 [1690952.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Am J Clin Pathol. 2000 Jun;113(6):784-91 [10874878.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] Histopathology. 2002 Mar;40(3):294-6 [11895498.001]
  • [Cites] Hematol Oncol. 2000 Mar;18(1):1-13 [10797525.001]
  • (PMID = 15650839.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


12. Assaad MW, Pantanowitz L, Otis CN: Diagnostic accuracy of image-guided percutaneous fine needle aspiration biopsy of the mediastinum. Diagn Cytopathol; 2007 Nov;35(11):705-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of image-guided percutaneous fine needle aspiration biopsy of the mediastinum.
  • Interpreting a fine needle aspiration biopsy (FNAB) from the mediastinum is challenging as this location may harbor many lesions, including primary and metastatic tumors.
  • The aim of this study was to determine the diagnostic accuracy of FNAB performed percutaneously for evaluating mediastinal lesions.A retrospective study of 157 consecutive CT-guided transthoracic FNAB of the mediastinum was performed (1988-2004).
  • Direct smears (N = 145; average 13 slides/case), ThinPrep slides (N = 25), and adequate cell blocks (N = 131) were prepared from procured cytologic material.
  • A definitive diagnosis was rendered in 128 (82%) cases.
  • Primary neoplasms (N = 38) included 24 lymphomas (6 Hodgkin and 18 non-Hodgkin), 7 thymomas, 1 thymic carcinoma, and 6 peripheral nerve sheath tumors.
  • There were 4 non-neoplastic lesions (1 granulomatous process; 2 bronchogenic and 1 pericardial cyst), 1 case of undifferentiated malignant large cell neoplasm, 13 cases negative for malignancy, and 29 (18%) that were indeterminate, due largely to insufficient cellularity.
  • There were 6 discordant cases, including 5 FNAB that were of adequate cellularity but interpreted as negative for malignant cells (on subsequent histology 2 turned out to be Hodgkin lymphoma, 2 carcinomas, and 1 diffuse large cell lymphoma), and 1 diagnosed as thymoma that on histologic evaluation was a thymic large cell lymphoma.
  • Adequate diagnostic cytologic material was obtained by image-guided percutaneous FNAB of mediastinal lesions in 82% of our cases.
  • Sufficient material was available to make cell blocks and perform ancillary studies when necessary.
  • These data also show a high proportion of agreement (78%) between FNAB and subsequent histologic diagnoses for a wide variety of mediastinal lesions.
  • The majority of discordant cases were primarily interpretive, with a final cytologic diagnosis negative for malignancy.
  • Only one problematic case misdiagnosed on FNAB as thymoma was found on subsequent surgical excision to be a thymic large B cell lymphoma.
  • Therefore, percutaneous FNAB of the mediastinum is a diagnostically helpful, minimally invasive procedure that can be performed in patients of all ages as part of the evaluation of a mediastinal mass lesion.
  • [MeSH-major] Biopsy, Fine-Needle. Mediastinal Neoplasms / diagnosis. Mediastinum / pathology. Surgery, Computer-Assisted

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17924408.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Rehm A, Anagnostopoulos I, Gerlach K, Broemer M, Scheidereit C, Jöhrens K, Hübler M, Hetzer R, Stein H, Lipp M, Dörken B, Höpken UE: Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int J Cancer; 2009 Nov 15;125(10):2367-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma.
  • Mediastinal large B-cell lymphomas (MLBCLs) are considered as a subtype of diffuse large B-cell lymphoma; however, they exhibit completely different patterns of dissemination.
  • Since they share a number of surface markers with thymic B cells, a close relationship was assumed.
  • MLBCLs arise extranodally within the anterior mediastinum and have a low propensity to metastasize.
  • To address the preferential positioning of MLBCL, we focused on homeostatic chemokines involved in B-cell compartmental homing in secondary lymphoid organs, which are also capable of shaping lymphoid niches in ectopic sites.
  • Flow cytometry was used to identify the chemokine receptor profile on an MLBCL-derived cell line, Karpas1106 and on thymic B cells.
  • Using immunohistochemistry, we obtained an unexpectedly low-expression frequency for the chemokine receptors CXCR5 and CCR7 in primary lesions.
  • Although the mature B-cell marker CCR6 was absent in most cases, the lineage aberrant marker CCR9 emerged in the majority of MLBCL cases.
  • MLBCLs exhibit a diagnostic chemokine receptor profile that is instrumental in the discrimination from diffuse large B-cell lymphoma not otherwise specified and classical Hodgkin lymphoma.
  • Furthermore, we suggest that low-abundance expression of CCR7 and CXCR5 may hinder lymphoma cells from nodal dissemination.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Mediastinal Neoplasms / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR5 / metabolism
  • [MeSH-minor] Adolescent. B-Lymphocytes / metabolism. Cell Movement. Cells, Cultured. Chemotaxis. Child. Child, Preschool. Electrophoretic Mobility Shift Assay. Flow Cytometry. Humans. Immunoenzyme Techniques. Infant. NF-kappa B / metabolism. Thymus Gland / cytology. Thymus Gland / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536742.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / CXCR5 protein, human; 0 / NF-kappa B; 0 / Receptors, CCR7; 0 / Receptors, CXCR5
  •  go-up   go-down


14. Milling DL, Lazarchick J, Chaudhary UB: Primary mediastinal large B-cell lymphoma in an HIV-infected patient. Am J Med Sci; 2005 Mar;329(3):136-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in an HIV-infected patient.
  • HIV-related non-Hodgkin lymphoma is well documented in the literature.
  • We report a case of an HIV-infected patient who presents with primary mediastinal large B-cell lymphoma.
  • On review of the literature, this appears to be the first documented case of this subtype of large B-cell non-Hodgkin lymphoma seen in an HIV-infected patient.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767818.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M: Isolated renal relapse of a case with non-Hodgkin's lymphoma. Med Oncol; 2010 Jun;27(2):434-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse of a case with non-Hodgkin's lymphoma.
  • A 29-year-old woman with left pleural effusion and a mass in anterior mediastinum was admitted.
  • The patient was in remission after six cycles of ABVD followed by mediastinal radiotherapy.
  • Ultrasound guided renal biopsy revealed diffuse large B cell lymphoma.
  • Retrospective re-evaluation of the archival specimens of the mediastinal mass was also consistent with diffuse large B cell lymphoma.
  • After induction chemotherapy (four cycles of DHAP) she underwent high dose chemotherapy (BEAM) and autologous peripheral blood stem cell transplantation.
  • In conclusion, renal involvement during advanced lymphoma is quite common but isolated renal relapse in NHL is a rare situation.
  • Although renal infiltration generally shows a poor prognosis, long-term survival may be achieved with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Female. Humans. Peripheral Blood Stem Cell Transplantation. Secondary Prevention

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Jan;173(1):239 [15592087.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):134-44 [7832273.001]
  • [Cites] Nephron Clin Pract. 2005;100(3):c86-91 [15824512.001]
  • [Cites] Urology. 1993 Sep;42(3):331-5 [8379037.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1733-8 [14692526.001]
  • [Cites] Hematol Oncol. 1990 Mar-Apr;8(2):105-10 [2344997.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3783-5 [17704429.001]
  • [Cites] Turk J Pediatr. 1989 Jan-Mar;31(1):71-7 [2692261.001]
  • [Cites] Eur Urol. 1986;12(5):352-4 [3780803.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2006 Sep;17(3):395-8 [16970262.001]
  • [Cites] Int Braz J Urol. 2006 Mar-Apr;32(2):190-2 [16650297.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 [18654120.001]
  • [Cites] Tumour Biol. 2003 Aug-Sep;24(4):172-5 [14654710.001]
  • [Cites] Am J Nephrol. 1994;14(2):148-53 [8080008.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):482-6 [9732229.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Gen Diagn Pathol. 1997 Feb;142(3-4):147-53 [9065578.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 Oct;24(4):586-9 [7942815.001]
  • [Cites] J Natl Med Assoc. 2003 Mar;95(3):220-4 [12749682.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):207-11 [9121151.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):154-9 [7517172.001]
  • (PMID = 19437146.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wang E, Stoecker M: Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature. Int J Hematol; 2010 Apr;91(3):509-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature.
  • We report the first case of primary mediastinal large B cell lymphoma (PMBL) with aberrant expression of CD3.
  • PMBL is a subtype of diffuse large B cell lymphoma (DLBCL) and usually presents with bulky mediastinal lesions.
  • Of the 14 total cases, 6 are pyothorax-associated lymphoma, 4 are conventional DLBCL, 2 are plasmablastic lymphoma, one is primary effusion lymphoma and one is PMBL.
  • [MeSH-major] Antigens, CD3 / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Radiography. Thymus Neoplasms / diagnostic imaging. Thymus Neoplasms / metabolism. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1092-101 [7943530.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):64-6 [9107085.001]
  • [Cites] Blood. 1992 Jul 1;80(1):209-16 [1319235.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):760-6 [8651357.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Feb;31(2):124-7 [19194198.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):426-9; quiz 526-7 [16931581.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Apr;9(2):133-7 [19406723.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):505-12 [19011566.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • (PMID = 20131102.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD3
  • [Number-of-references] 15
  •  go-up   go-down


17. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood; 2010 Oct 28;116(17):3268-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
  • Classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (MLBCL) are lymphoid malignancies with certain shared clinical, histologic, and molecular features.
  • Primary cHLs and MLBCLs include variable numbers of malignant cells within an inflammatory infiltrate, suggesting that these tumors escape immune surveillance.
  • Herein, we integrate high-resolution copy number data with transcriptional profiles and identify the immunoregulatory genes, PD-L1 and PD-L2, as key targets at the 9p24.1 amplification peak in HL and MLBCL cell lines.
  • We extend these findings to laser-capture microdissected primary Hodgkin Reed-Sternberg cells and primary MLBCLs and find that programmed cell death-1 (PD-1) ligand/9p24.1 amplification is restricted to nodular sclerosing HL, the cHL subtype most closely related to MLBCL.
  • Using quantitative immunohistochemical methods, we document the association between 9p24.1 copy number and PD-1 ligand expression in primary tumors.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4965-72 [15256470.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 25;23(20):4097-103 [7479071.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W393-6 [15980497.001]
  • [Cites] J Leukoc Biol. 2005 Nov;78(5):1043-51 [16204623.001]
  • [Cites] FEBS Lett. 2006 Feb 6;580(3):755-62 [16413538.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6844-52 [17121906.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2151-7 [17404099.001]
  • [Cites] Bioinformatics. 2007 Mar 15;23(6):657-63 [17234643.001]
  • [Cites] Blood. 2007 Jul 1;110(1):296-304 [17363736.001]
  • [Cites] Immunity. 2007 Jul;27(1):111-22 [17629517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9 [17670934.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3226-33 [17644739.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7466-77 [18025191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):318-22 [17637749.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3220-4 [18203952.001]
  • [Cites] Annu Rev Immunol. 2008;26:677-704 [18173375.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3044-51 [18483370.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Cancer Lett. 2008 Sep 8;268(1):98-109 [18486325.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Sep;134(9):1021-7 [18347814.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20428-33 [19075244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7 [19088198.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):971-9 [19188168.001]
  • [Cites] Immunol Rev. 2009 Jul;230(1):144-59 [19594634.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2945-51 [19666866.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1715-22 [19695683.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4503-6 [19734449.001]
  • [Cites] J Exp Med. 2009 Dec 21;206(13):3015-29 [20008522.001]
  • [Cites] Cancer. 2010 Apr 1;116(7):1757-66 [20143437.001]
  • [Cites] Clin Cancer Res. 2010 Apr 1;16(7):1988-96 [20215535.001]
  • [Cites] Blood. 2010 Jul 22;116(3):418-27 [20339089.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Immunol Lett. 2002 Oct 21;84(1):57-62 [12161284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 [12218188.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Eur J Immunol. 2003 Oct;33(10):2706-16 [14515254.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2308-18 [18723478.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • (PMID = 20628145.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA092625
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / PDCD1LG2 protein, human; 0 / Programmed Cell Death 1 Ligand 2 Protein; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2995356
  •  go-up   go-down


18. Oberson M, Zucca E, Mazzucchelli L, Menafoglio A, Guerra A, Gallino A: Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma. Br J Haematol; 2009 Feb;144(3):277
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / ultrasonography. Pulmonary Artery / ultrasonography. Thymus Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19149803.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, Mattfeldt T, Barth TF, Möller P: Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene; 2006 Apr 27;25(18):2679-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.
  • SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas.
  • Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma (PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P.
  • For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5.
  • Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL).
  • We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma (HL)-derived cell lines by sequencing analysis.
  • Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.
  • [MeSH-major] Cell Nucleus / metabolism. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Hodgkin Disease / genetics. Intracellular Signaling Peptides and Proteins / genetics. Mutation. Repressor Proteins / genetics. STAT5 Transcription Factor / metabolism. Suppressor of Cytokine Signaling Proteins / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532038.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / STAT5 Transcription Factor; 0 / Suppressor of Cytokine Signaling Proteins
  •  go-up   go-down


20. Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, Jaffe ES: Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol; 2005 Nov;29(11):1411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
  • In recent years, overlap in biologic and morphologic features has been identified between classic Hodgkin lymphoma (cHL) and B-cell non-Hodgkin lymphoma.
  • We undertook a study of "mediastinal gray zone lymphomas" (MGZL), with features transitional between cHL nodular sclerosis (NS) and primary mediastinal large B-cell lymphoma (MLBCL) to better understand the morphologic and immunophenotypic spectrum of such cases.
  • We also studied 6 cases of composite or synchronous lymphoma with two distinct components at the same time (cHL-NS and MLBCL) and 9 sequential cases with MLBCL and cHL-NS at different times.
  • All patients had a large mediastinal mass.
  • Immunohistochemical studies focused on markers known to discriminate between cHL and MLBCL, including B-cell transcription factors.
  • Of the gray zone cases, 11 had morphology reminiscent of cHL-NS, but with unusual features, including a large number of mononuclear variants, diminished inflammatory background, absence of classic Hodgkin phenotype, and strong CD20 expression (11 of 11).
  • B-cell transcription factor expression in the gray zone cases more closely resembled MLBCL than cHL with expression of Pax5, Oct2, and BOB.1 in all but 1 case studied (14 of 15).
  • Two cases of sequential lymphoma showed rearrangements of the IgH gene of identical size: one in which MLBCL was the first diagnosis and one in which MLBCL was diagnosed at relapse, indicating clonal identity for the two components of cHL and MLBCL.
  • Further support for a relationship between MLBCL and cHL-NS is provided by composite and metachronous lymphomas in the same patient, as well as the existence of MGZL with transitional morphology and phenotype.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Mediastinal Neoplasms / pathology


21. Massoud M, Koscielny S, Lapusan S, Bosq J, Ribrag V: Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Leuk Lymphoma; 2008 Aug;49(8):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.
  • We retrospectively reviewed 105 cases of primary mediastinal large B-cell lymphoma (PMLBL).
  • Radiotherapy was delivered to patients with a lymphoma proven sensitive to CHOP who could receive irradiation for localised disease.
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766963.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. García JF, Mollejo M, Fraga M, Forteza J, Muniesa JA, Pérez-Guillermo M, Pérez-Seoane C, Rivera T, Ortega P, Piris MA: Large B-cell lymphoma with Hodgkin's features. Histopathology; 2005 Jul;47(1):101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma with Hodgkin's features.
  • AIMS: To describe the features of a series of nine cases of diffuse large B-cell lymphoma (DLBCL) showing morphological and immunophenotypic features that are intermediate with Hodgkin's lymphoma (HL).
  • METHODS AND RESULTS: Most cases (6/9) presented as mediastinal tumours affecting young males, while the other three cases arose in extramediastinal locations.
  • Histopathologically, tumours showed diffuse large cell areas in a polymorphous background, with pleomorphic cytology and the common presence of Hodgkin's and Reed-Sternberg cells.
  • Immunophenotypically, tumours shared features of DLBCL and classical HL, with expression of CD30, CD15 (6/9), and a full B-cell profile including CD45RB, CD20, CD79a and OCT2.
  • The majority of tumours had immunohistochemical features consistent with activation of the NF-(kappa)B pathway, including nuclear location of the c-REL/p65 subunit, overexpression of phosphorylated I(kappa)B(alpha), and overexpression of NF-(kappa)B targets.
  • CONCLUSIONS: These findings suggest that DLBCLs with HL features constitute a distinctive subgroup of aggressive lymphomas whose neoplastic growth and peculiar characteristics could be facilitated by a particular microenvironment found in the mediastinum.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Middle Aged. Mutation. Neoplasm Staging. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Transcription Factors / genetics. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982329.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Melzner I, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Barth TF, Leithäuser F, Möller P: Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood; 2005 Mar 15;105(6):2535-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
  • Primary mediastinal B-cell lymphoma (PMBL) is a well-defined subtype of diffuse large B-cell lymphoma.
  • JAK2, mapping in this region, is presently regarded as a candidate oncogene because expression profiling showed high Janus kinase-2 (JAK2) transcript levels and JAK2 was found to be constitutively phosphorylated in mediastinal B-cell lymphomas.
  • We confirm that in the MedB-1 mediastinal B-cell line, harboring a trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated.
  • This unexpected finding coincides with a biallelic mutation of the suppressor of cytokine signaling-1 (SOCS-1) gene in this cell, which abrogates SOCS box function of the protein.
  • Ectopic expression of wild-type (wt) SOCS-1 in MedB-1 leads to growth arrest and dramatic reduction of phospho-JAK2 and its downstream partner phospho-signal transducer and activator of transcription-5 (phospho-STAT5).
  • Of note, SOCS-1 mutations are also present in the parental tumor of MedB-1 and were detected in 9 of 20 PMBLs.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / genetics. Lymphoma, B-Cell / metabolism. Mediastinal Neoplasms / metabolism. Mutation. Protein Processing, Post-Translational / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Suppressor of Cytokine Signaling Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Alleles. Cell Line, Tumor. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / metabolism. Cyclin D1 / genetics. Cyclin D1 / metabolism. Gene Expression Regulation, Leukemic / genetics. Humans. Janus Kinase 2. Phosphorylation. Retinoblastoma Protein / genetics. Retinoblastoma Protein / metabolism. STAT5 Transcription Factor / genetics. STAT5 Transcription Factor / metabolism. Signal Transduction / genetics. Trisomy / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15572583.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Retinoblastoma Protein; 0 / SOCS1 protein, human; 0 / STAT5 Transcription Factor; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


24. Martelli M, Ferreri AJ, Johnson P: Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol; 2008 Dec;68(3):256-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma (PMLBCL) is a unique type of B-cell lymphoma probably arising from a putative thymic medulla B-cell.
  • It constitutes 6-10% of all diffuse large B-cell lymphomas (DLBCL), occurring more often in young females.
  • PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis and a degree of compartmentalisation.
  • The gene expression signature of PMLBCL seems to be much closer to classic Hodgkin lymphoma than to DLBCL.
  • PMLBCL is characterized by a locally invasive anterior mediastinal mass, often producing cough, chest pain, dyspnea, and superior vena cava syndrome.
  • Features associated with poor prognosis are poor performance status, pericardial effusion, bulky disease, high serum LDH at diagnosis, and a compromised dose-intensity of anthracycline and cyclophosphamide.
  • [MeSH-major] Lymphoma, B-Cell. Mediastinal Neoplasms

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774728.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 75
  •  go-up   go-down


25. Zamò A, Malpeli G, Scarpa A, Doglioni C, Chilosi M, Menestrina F: Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. Mod Pathol; 2005 Nov;18(11):1448-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas.
  • Primary mediastinal large B-cell lymphoma is a well-defined lymphoma entity whose molecular pathogenesis is incompletely understood and also lacking well-established diagnostic markers.
  • Recently, the presence of overlapping features between classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma was highlighted by gene expression profiling as well as morphological studies.
  • We investigated the expression of TP73L (commonly known as p63) isoforms in primary mediastinal large B-cell lymphoma at both protein and mRNA level, and demonstrated the exclusive presence of transactivating (TA) isoforms in all cases.
  • We also demonstrated that TP73L is expressed in a subset of germinal center B-cells, as well as in some diffuse large B-cell lymphomas, but it is never present in classical Hodgkin lymphoma.
  • Nodular lymphocyte predominant Hodgkin's lymphoma also showed TP73L positivity by immunohistochemistry.
  • Isoform analysis by real-time PCR showed that TA-TP73Lalpha is the most represented in primary mediastinal large B-cell lymphoma, but TA-TP73Lgamma is the most differentially expressed in comparison to both germinal center B-cells and diffuse large B-cell lymphomas.
  • TP73L expression proved a useful diagnostic marker of primary mediastinal large B-cell lymphoma, and gave new insights in to the molecular pathways playing a role in this lymphoma.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Phosphoproteins / biosynthesis. Trans-Activators / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA-Binding Proteins. Diagnosis, Differential. Gene Expression. Gene Expression Profiling. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Protein Isoforms / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Modern Pathology (2005) 18, 1448-1453. doi:10.1038/modpathol.3800440; published online 13 May 2005.
  • (PMID = 15920542.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


26. Popov SW, Moldenhauer G, Wotschke B, Brüderlein S, Barth TF, Dorsch K, Ritz O, Möller P, Leithäuser F: Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma. Cancer Res; 2007 Jul 15;67(14):6555-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma.
  • Activation-induced cytidine deaminase (AID) initiates somatic hypermutation (SHM) and class switch recombination (CSR) in activated B lymphocytes and is potentially implicated in genomic instability of B-cell malignancies.
  • For unknown reasons, B-cell neoplasms often lack SHM and CSR in spite of high AID expression.
  • Here, we show that primary mediastinal B-cell lymphoma (PMBL), an immunoglobulin (Ig)-negative lymphoma that possesses hypermutated, class-switched Ig genes, expresses high levels of AID with an intact primary structure but does not do CSR in 14 of 16 cases analyzed.
  • Interleukin-4/CD40L costimulation induced CSR and a marked up-regulation of germ-line transcription in the PMBL-derived cell line MedB-1.
  • In the PMBL cell line Karpas 1106P, CSR was not inducible and germ-line transcription remained low on stimulation.
  • Thus, accessibility of the target sequences seems to be a major limiting factor for AID-dependent somatic gene diversification in PMBL.
  • [MeSH-major] Cytidine Deaminase / biosynthesis. Cytidine Deaminase / chemistry. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cloning, Molecular. Cyclic AMP-Dependent Protein Kinases / metabolism. Genes, Immunoglobulin. Humans. Immunoglobulin Class Switching. Mediastinal Neoplasms / metabolism. RNA, Messenger / metabolism. Transcription, Genetic. Transfection. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638864.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


27. Salama ME, Rajan Mariappan M, Inamdar K, Tripp SR, Perkins SL: The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. Int J Surg Pathol; 2010 Apr;18(2):121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma.
  • Mediastinal diffuse large B-cell lymphoma (Med-DLBCL) is a subtype of DLBCL that has morphologic and clinical similarities and phenotypic overlaps with classical Hodgkin lymphoma (CHL) involving the mediastinum.
  • CD23 is a marker that has been previously reported in Med-DLBCI and is proposed in the differential diagnosis of M-DLBCL and CHL.
  • In conclusion CD23 is a useful marker in distinguishing Med-DLBCL and CHL in mediastinal biopsies and may be helpful as an adjunct to histomorphology and other markers in the diagnosis and appropriate clinical management of these lesions.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Receptors, IgE / metabolism. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Reed-Sternberg Cells / pathology. Retrospective Studies. Young Adult


28. Clarke JR, Brglevska S, Lau EW, Ramdave S, Hicks RJ: Atypical brown fat distribution in young males demonstrated on PET/CT. Clin Nucl Med; 2007 Sep;32(9):679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other described sites of uptake include the mediastinum and retroperitoneum.
  • We present examples of 2 cases of atypical diffuse brown fat uptake seen in the subcutaneous fat of the thighs, abdomen, and pelvis.
  • Although rare in our experience, knowledge of this condition may prevent misinterpretation of this finding as an infiltrative condition of the skin, such as lymphoma.
  • [MeSH-minor] Adolescent. False Positive Reactions. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Rhabdomyosarcoma, Alveolar / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710017.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, Möller P, Barth TF: Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer; 2007 Apr;46(4):406-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein.
  • Gains or amplifications of the REL locus are frequently seen in primary mediastinal B-cell lymphoma (PMBL).
  • In classical Hodgkin's lymphoma, genomic overrepresentation of REL correlated with nuclear REL protein accumulation.
  • To investigate the correlation between REL gene copies and its RNA and protein expression in PMBL, we analyzed genomic, transcriptional, and protein levels in 20 PMBLs and the PMBL derived cell lines MedB-1 and Karpas1106P.
  • We found gains/amplifications in 75% of the PMBLs by fluorescence in situ hybridization (FISH) and genomic REL overrepresentation in the PMBL lines.
  • Three of the five PMBLs with amplifications displayed elevated REL transcripts, while only 3/10 PMBLs with gains showed increased REL transcripts by real-time PCR.
  • One PMBL without gains displayed increased REL transcription.
  • REL protein expression exhibited a variable pattern across the PMBLs except for a single case that was completely negative by immunohistochemistry despite having gained REL.
  • Although transcript levels were generally low and nuclear REL staining was weak in the lymphoma cell lines, these nevertheless exhibited high NF-kappaB activation.
  • In conclusion, the frequent genomic overrepresentation of REL in PMBL does not necessarily trigger an increased transcription/translation of REL.
  • However, combined genomic and protein analysis revealed a significant association of gained REL and nuclear REL accumulation at the single cell level.
  • [MeSH-major] Cell Nucleus / metabolism. Lymphoma, B-Cell / metabolism. Mediastinal Neoplasms / metabolism. Proto-Oncogene Proteins c-rel / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17243160.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-rel
  •  go-up   go-down


30. Barth TF, Melzner I, Wegener S, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Leithäuser F, Möller P: [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line]. Verh Dtsch Ges Pathol; 2005;89:234-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line].
  • [Transliterated title] Die biallelische Mutation von SOCS-1 verhindert den Abbau von JAK2 und prolongiert die Wirkung von phospho-JAK2 in der mediastinalen B-Zell Lymphomlinie MedB-1.
  • Primary mediastinal B-cell lymphoma (PMBL) is a well-defined subtype of diffuse large B-cell lymphoma.
  • JAK2, mapping in this region, is presently regarded as a candidate oncogene since expression profiling showed high JAK2 transcript levels and JAK2 was found to be constitutively phosphorylated in mediastinal B-cell lymphomas.
  • We confirm that in the MedB-1 mediastinal B-cell line, harbouring a trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated.
  • This unexpected finding coincides with a biallelic mutation of the SOCS-1 gene in this cell, which abrogates SOCS box function of the protein.
  • Of note, the SOCS-1 mutations are also present in the parental tumor of MedB-1 and were detected in 9 of 20 PMBL.
  • [MeSH-major] Janus Kinase 2 / metabolism. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics. Mutation. Suppressor of Cytokine Signaling Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035697.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


31. Hoda RS, Picklesimer L, Green KM, Self S: Fine-needle aspiration of a primary mediastinal large B-cell lymphoma: a case report with cytologic, histologic, and flow cytometric considerations. Diagn Cytopathol; 2005 Jun;32(6):370-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of a primary mediastinal large B-cell lymphoma: a case report with cytologic, histologic, and flow cytometric considerations.
  • Fine-needle aspiration (FNA) cytology and immunophenotyping by flow cytometry (FCM) are increasingly being used for diagnosing and subclassifying lymphoma in the REAL/WHO classification.
  • Herein, we report a case of primary mediastinal large B-cell lymphoma (PMBL), a subtype of diffuse large B-cell lymphoma in the WHO classification, diagnosed by FNA cytology in conjunction with FCM.
  • CT scan revealed a 5-cm anterior mediastinal mass and mediastinal lymphadenopathy.
  • Endoscopic ultrasound-guided FNA of a 4.5-cm subcarinal lymph node showed medium to large atypical lymphocytes with scant to moderate finely vacuolated cytoplasm.
  • Malignant large cell lymphoma was cytologically diagnosed.
  • FCM, performed on a portion of the FNA specimen, demonstrated large B cells devoid of surface immunoglobulin expression, the characteristic immunophenotype of PMBL.
  • The histologic diagnosis was PMBL.
  • Touch-imprint cytology of the histologic specimen showed large cells with a narrow rim of clear cytoplasm and prominent outer cell border.
  • In the presence of a mediastinal mass, FNA cytology in conjunction with FCM can effectively diagnose PMBL in the appropriate clinical setting.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Biopsy, Fine-Needle. Female. Flow Cytometry. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880713.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


32. Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol; 2005 Oct;207(2):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.
  • In a previous study we demonstrated high expression of the non-coding BIC gene in the vast majority of Hodgkin's lymphomas (HLs).
  • Evidence suggesting that BIC is a primary microRNA transcript containing the mature microRNA-155 (miR-155) as part of a RNA hairpin is now accumulating.
  • We therefore analysed HL cell lines and tissue samples to determine whether miR-155 is also expressed in HL.
  • However, in diffuse large B cell lymphoma (DLBCL) and primary mediastinal B cell lymphoma (PMBL), significant percentages of positive tumour cells were observed in 12/18 and 8/8 cases.
  • A higher proportion of tumour cells were positive for BIC in DLBCL with activated B cell-like phenotype than in DLBCL with germinal centre B cell-like phenotype.
  • Northern blot analysis showed expression of miR-155 in all DLBCL and PMBL derived cell lines and tissue samples analysed.
  • In summary, we demonstrate expression of primary microRNA BIC and its derivative miR-155 in HL, PMBL and DLBCL.
  • [MeSH-major] Lymphoma / genetics. Mediastinal Neoplasms / genetics. MicroRNAs / genetics. Receptors, Antigen, B-Cell / genetics
  • [MeSH-minor] Cell Line, Tumor. Hodgkin Disease / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041695.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


33. Johnson PW, Davies AJ: Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program; 2008;:349-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal B-cell lymphoma.
  • Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity.
  • Molecular analysis reveals it to be distinct from other types of large B-cell lymphoma, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP.
  • The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual mediastinal masses.
  • For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the de-escalation of treatment if it can be shown to yield reliable prognostic information.
  • The relative rarity of this type of lymphoma necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074109.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 77
  •  go-up   go-down


34. Sambade C, Berglund M, Lagercrantz S, Sällström J, Reis RM, Enblad G, Glimelius B, Sundström C: U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int J Cancer; 2006 Feb 1;118(3):555-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma.
  • Several patterns of association between Hodgkin and non-Hodgkin lymphomas are recognized, some of which support a common cellular origin or shared transformation events for both malignancies.
  • We describe the U-2940 cell line derived from a diffuse large B-cell lymphoma with some features consistent with mediastinal large B-cell lymphoma, clinically apparent 1 month after the initial course of chemotherapy for Hodgkin's disease, fulfilling the criteria for composite malignancies.
  • The cell line is negative for Epstein-Barr virus and no evidence of t(14;18) was found.
  • U-2940 cells display multiple chromosomal rearrangements similar to recurrent aberrations described in both Hodgkin and non-Hodgkin lymphomas, also partially shared by U-2932 derived from a B-cell lymphoma sequential to Hodgkin's disease.
  • The original large B-cell lymphoma and the U-2940 cell line bear microsatellite instability, an abnormality associated with particular subtypes of non-Hodgkin lymphomas and found in tissues involved by Hodgkin lymphoma.
  • Therefore, U-2940 cells bear several features known to occur in Hodgkin and in non-Hodgkin lymphomas, leading to the assumption that this cell line may constitute a useful tool to address elective pathways of lymphomagenesis and eventually the Hodgkin and non-Hodgkin lymphoma association.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Colony-Forming Units Assay. DNA, Neoplasm / analysis. Epstein-Barr Virus Infections / etiology. Epstein-Barr Virus Infections / pathology. Female. Gene Rearrangement. Herpesvirus 4, Human / pathogenicity. Humans. Immunoglobulin Heavy Chains / genetics. Mice. Mice, Nude. Spectral Karyotyping. Translocation, Genetic


35. Kolonić SO, Dzebro S, Kusec R, Planinc-Peraica A, Dominis M, Jaksić B: Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics. Int J Hematol; 2006 May;83(4):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics.
  • Primary mediastinal large B-cell lymphoma (PMLBCL) is a subset of LBCL with unique clinicopathologic features.
  • [MeSH-major] Lymphoma, B-Cell / blood. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / blood. Mediastinal Neoplasms / pathology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):139-46 [10512171.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Br J Haematol. 1995 Apr;89(4):780-9 [7539625.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):295-306 [9517501.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):465-71 [15239397.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1277-82 [11688462.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2306-13 [8246020.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):691-9 [16115124.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1855-64 [11251018.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2017-25 [8669486.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1027-9 [9818079.001]
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):312-6 [15170155.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):361-5 [10752987.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):784-90 [10071267.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3567-75 [10552968.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):730-9 [2788371.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):804-8 [1692089.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):372-6 [14735179.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):241-7 [10439805.001]
  • (PMID = 16757434.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


36. Vides Almonacid G, García A, Denninghoff V, Avagnina A, Castiglioni T, Elsner B: [Flow cytometry for the study of mediastinal tumors with abundant lymphoid elements]. Medicina (B Aires); 2008;68(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometry for the study of mediastinal tumors with abundant lymphoid elements].
  • [Transliterated title] La citometría de flujo en el estudio de tumores mediastinales ricos en elementos linfoides.
  • The anterior mediastinum is a common site of tumors with abundant lymphoid elements.
  • Flow cytometry is a useful complementary technique to analyze this type of tumors, which provides qualitative and quantitative information.
  • A differential diagnosis can be sometimes made between thymoma and precursor T-lymphoblastic lymphoma (T-LBL).
  • A total of 38 mediastinal tumors were analyzed, and samples were separated for flow cytometry.
  • Flow cytometry data from thymomas and normal thymic tissue were compared with 42 cases of T-LBL from other anatomical locations.
  • Among 38 mediastinal tumors, we found 6 benign lesions, 9 diffuse large B-cell lymphomas (DLBCL), 10 Hodgkin lymphomas (HL), 11 thymomas and 2 T-LL.
  • Flow cytometry helped differentiate 10 cases of HL and 4 benign lesions from other lymphomas (DLBCL, T-LBL, etc.).
  • CD3, CD4 and CD8 expressions were most useful for the differential diagnosis of thymomas and T-LL.
  • To conclude, flow cytometry is a valid complementary technique, which promptly provides information on mediastinal lesions, requiring small quantities of tissue for both early diagnosis and follow up of these diseases.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor. Flow Cytometry. Mediastinal Neoplasms / pathology. Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416319.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Stefoni V, Broccoli A, Pellegrini C, Derenzini E, Fina M, Zinzani PL: CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. J Neurooncol; 2009 Oct;95(1):135-139
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2007 Jan;18(1):149-57 [17018708.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):685-90 [10942056.001]
  • [Cites] Ann Intern Med. 1985 May;102(5):596-602 [2580468.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):576-80 [12209750.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):361-3 [8819088.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):335-45 [16942676.001]
  • [Cites] Oncologist. 2006 May;11(5):488-95 [16720849.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2306-13 [8246020.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:283-96 [12446428.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] Ann Hematol. 1998 Nov;77(5):239-42 [9858151.001]
  • [Cites] Ann Hematol. 2000 Dec;79(12):696-9 [11195008.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2479-85 [10561312.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1027-9 [9818079.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):571-6 [10048430.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3034-41 [7954266.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2486-92 [7139540.001]
  • [Cites] Ann Hematol. 2003 Apr;82(4):241-3 [12707728.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1099-107 [12176790.001]
  • [Cites] Leuk Lymphoma. 2008;49 Suppl 1:52-8 [18821433.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1364-71 [18603558.001]
  • [Cites] Haematologica. 2001 Feb;86(2):187-91 [11224489.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1783-8 [12685832.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Haematologica. 2006 Jan;91(1):96-103 [16434377.001]
  • (PMID = 19381440.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Complement 3d; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases
  •  go-up   go-down


38. Bödör C, Bognár A, Reiniger L, Szepesi A, Tóth E, Kopper L, Matolcsy A: Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br J Haematol; 2005 May;129(3):373-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma.
  • To determine the possible role of aberrant somatic hypermutation (ASHM) and activation-induced cytidine deaminase (AID) expression in the pathogenesis of mediastinal large B-cell lymphoma (MBL), the mutational status of genes affected by ASHM, including c-MYC, PAX-5 and RhoH, was analysed, and the expression level of AID mRNA in tumour specimens from six patients with MBL was determined.
  • [MeSH-major] Cytidine Deaminase / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics. Somatic Hypermutation, Immunoglobulin
  • [MeSH-minor] B-Cell-Specific Activator Protein. DNA Mutational Analysis. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Gene Expression. Genes, myc / genetics. Humans. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Transcription Factors / genetics. rho GTP-Binding Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842661.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / PAX5 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RhoH protein, human; 0 / Transcription Factors; EC 3.5.4.5 / Cytidine Deaminase; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


39. Tsai HW, Yen YS, Chang KC: Mediastinal large B-cell lymphoma with rosette formation mimicking thymoma and thymic carcinoid. Histopathology; 2006 Jul;49(1):93-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal large B-cell lymphoma with rosette formation mimicking thymoma and thymic carcinoid.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carcinoid Tumor / diagnosis. Diagnosis, Differential. Female. Humans. Rosette Formation. Thymoma / diagnosis. Thymus Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842255.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


40. Juul-Madsen HR, Krogh-Meibom T, Henryon M, Palaniyar N, Heegaard PM, Purup S, Willis AC, Tornøe I, Ingvartsen KL, Hansen S, Holmskov U: Identification and characterization of porcine mannan-binding lectin A (pMBL-A), and determination of serum concentration heritability. Immunogenetics; 2006 Apr;58(2-3):129-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of porcine mannan-binding lectin A (pMBL-A), and determination of serum concentration heritability.
  • Although two MBLs (MBL-A and MBL-C) have been characterized in various species, the identity of porcine MBL (pMBL) was not clearly defined.
  • Based on the N-terminal sequence, multiple sequence alignment, and relative affinities to various carbohydrate ligands, we propose that the MBL purified in this study is pMBL-A.
  • We have generated antibodies to this protein and established an immunoassay to quantify pMBL-A in serum.
  • Using this assay, we found breed differences in pMBL-A concentration distributions and heritability estimates.
  • In the Duroc breed (n=588), pMBL-A concentrations show a unimodal distribution with a mean of 9,125 ng/ml.
  • In contrast, the pMBL-A concentration distributions in the Landrace breed (n=533) show three distinct mean values: 301, 2,385, and 11,507 ng/ml.
  • Furthermore, heritability calculations based on an additive genetic variance model with no fixed effects indicate that serum pMBL-A concentration is highly heritable in the Landrace (h (2)=0.8) but not in the Duroc breed (h (2)=0.15).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32728-36 [15145932.001]
  • [Cites] Immunology. 2001 Mar;102(3):338-43 [11298833.001]
  • [Cites] Mol Immunol. 2003 Sep;40(2-4):73-84 [12914814.001]
  • [Cites] Immunopharmacology. 1992 Sep-Oct;24(2):91-9 [1473968.001]
  • [Cites] Biochem Soc Trans. 2003 Aug;31(Pt 4):753-7 [12887297.001]
  • [Cites] Annu Rev Immunol. 2002;20:197-216 [11861602.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):878-87 [10878362.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1497-502 [1460414.001]
  • [Cites] J Immunol. 1995 Sep 15;155(6):3013-20 [7673719.001]
  • [Cites] Scand J Immunol. 1996 Mar;43(3):289-96 [8602463.001]
  • [Cites] J Immunol. 1993 Jan 15;150(2):571-8 [8419490.001]
  • [Cites] Immunity. 2001 Jul;15(1):127-35 [11485744.001]
  • [Cites] Immunol Rev. 2001 Apr;180:86-99 [11414367.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):506-10 [9087411.001]
  • [Cites] FEBS Lett. 1975 Sep 15;57(2):187-91 [1175787.001]
  • [Cites] Immunobiology. 1998 Aug;199(2):165-89 [9777404.001]
  • [Cites] Nature. 1992 Nov 12;360(6400):183-6 [1279438.001]
  • [Cites] Nature. 1992 Nov 12;360(6400):127-34 [1436090.001]
  • [Cites] Scand J Immunol. 2001 May;53(5):489-97 [11309157.001]
  • [Cites] Immunol Today. 1996 Nov;17(11):532-40 [8961631.001]
  • [Cites] FEBS Lett. 1994 May 16;344(2-3):191-5 [8187882.001]
  • [Cites] Biochem J. 1996 Oct 15;319 ( Pt 2):329-32 [8912663.001]
  • [Cites] Mol Immunol. 2003 Nov;40(7):423-9 [14568388.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2610-8 [10679100.001]
  • (PMID = 16518621.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Mannose-Binding Lectin; 0 / Monosaccharides
  •  go-up   go-down


41. Miyake GM, Newton SE, Mariott WR, Chen EY: Coordination polymerization of renewable butyrolactone-based vinyl monomers by lanthanide and early metal catalysts. Dalton Trans; 2010 Aug 7;39(29):6710-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The resulting atactic PMBL and PMMBL have high T(g)'s of 194 degrees C and 227 degrees C, respectively; when compared to atactic PMMA having comparable MW, the T(g) and onset decomposition temperatures of the PMMBL produced are substantially higher (by approximately 120 degrees C and 40 degrees C, respectively).
  • In comparison, the polymerizations by non-lanthanocene(III) silylamides, Ln[N(SiMe(3))(2)](3) (Ln = La, Nd, Sm, Er), and by cationic group 4 metallocene and half-metallocene catalysts incorporating C(2) and C(s) symmetric ligands are much slower and less effective.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631950.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Konety SH, Wooldridge JE, Kerber RE: Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography. Echocardiography; 2006 Feb;23(2):147-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography.
  • Primary cardiac lymphomas are extremely rare and can be diagnosed by echocardiography.
  • We present the case of a 79-year-old man with an intracardiac mass, shown to be an aggressive large B-cell lymphoma by mediastinal aspiration, who had rapid regression of the tumor following one cycle of chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445735.001).
  • [ISSN] 0742-2822
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Gualco G, Weiss LM, Barber GN, Bacchi CE: T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Hum Pathol; 2010 Sep;41(9):1238-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
  • The physiologic expression of the product of the proto-oncogene TCL1 (T-cell leukemia 1) is primarily restricted to early embryonic cells.
  • It has been shown that TCL1 is a powerful B-cell oncogene, which has been implicated in the pathogenesis of various types of mature B-cell lymphomas.
  • There is no comparative information in the literature addressing the expression of TCL1 in pediatric and adult nodal diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
  • We studied 55 cases of adult and pediatric diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma to analyze the phenotypic profile of these lymphomas, including TCL1 expression, and its relationship with clinical outcome in different age groups.
  • TCL1 was observed in 11 cases, 5 pediatric and 6 adult cases, all but one diffuse large B-cell lymphoma.
  • TCL1 positivity was predominantly found in germinal center phenotype diffuse large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphomas infrequently expressed TCL1 in both age groups.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Mediastinal Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20382409.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TCL1A protein, human
  •  go-up   go-down


44. Mazzarotto R, Boso C, Vianello F, Aversa MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D, Sotti G: Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):823-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
  • PURPOSE: The optimal therapy for primary mediastinal large B-cell lymphoma (PMLBCL) remains undefined.
  • In the absence of randomized trials, we report clinical findings and treatment response in 53 consecutive patients treated with intensive chemotherapy and mediastinal involved-field radiation therapy (IFRT).
  • CONCLUSIONS: Our report confirms the efficacy of intensive chemotherapy plus mediastinal IFRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Incidence. Italy / epidemiology. Male. Mediastinum. Middle Aged. Prognosis. Risk Assessment / methods. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379431.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ikegame K, Kawakami M, Yamagami T, Maeda H, Onishi K, Taniguchi Y, Fujioka T, Masuda T, Kawase I, Ogawa H: HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism. Clin Lab Haematol; 2005 Apr;27(2):139-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism.
  • There are few reports of unmanipulated HLA-haploidentical nonmyeloablative stem cell transplantation (NST) using only pharmacological acute graft-vs.-host disease (GVHD) prophylaxis.
  • We present here a successful case of unmanipulated HLA-haploidentical NST for mediastinal large B cell lymphoma that was resistant to autologous peripheral blood stem cell transplantation (PBSCT).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing
  • [MeSH-minor] Adult. Female. Graft Survival. Graft vs Host Disease / prevention & control. Haplotypes. Humans. Immunosuppression / methods. Lymphoma, B-Cell / therapy. Mediastinal Neoplasms / therapy. Transplantation Chimera. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784130.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Mottok A, Renné C, Seifert M, Oppermann E, Bechstein W, Hansmann ML, Küppers R, Bräuninger A: Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood; 2009 Nov 12;114(20):4503-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.
  • In primary mediastinal large B-cell lymphoma and Hodgkin lymphoma (HL), inactivating mutations in SOCS1, an inhibitor of JAK/STAT signaling, contribute to deregulated STAT activity.
  • Based on indications that the SOCS1 mutations are caused by the B cell-specific somatic hypermutation (SHM) process, we analyzed B-cell non-HL and normal B cells for mutations in SOCS1.
  • One-fourth of diffuse large B-cell lymphoma and follicular lymphomas carried SOCS1 mutations, which were preferentially targeted to SHM hotspot motifs and frequently obviously inactivating.
  • Rare mutations were observed in Burkitt lymphoma, plasmacytoma, and mantle cell lymphoma but not in tumors of a non-B-cell origin.
  • Mutations in single-sorted germinal center B cells were infrequent relative to other genes mutated as byproducts of normal SHM, indicating that SOCS1 inactivation in primary mediastinal large B-cell lymphoma, HL, diffuse large B-cell lymphoma, and follicular lymphoma is frequently the result of aberrant SHM.
  • [MeSH-major] Lymphoma, B-Cell / genetics. Somatic Hypermutation, Immunoglobulin / genetics. Suppressor of Cytokine Signaling Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734449.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins
  •  go-up   go-down


47. Vanhentenrijk V, Vanden Bempt I, Dierickx D, Verhoef G, Wlodarska I, De Wolf-Peeters C: Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling. J Pathol; 2006 Oct;210(2):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between classic Hodgkin lymphoma and overlapping large cell lymphoma investigated by comparative expressed sequence hybridization expression profiling.
  • There is a diagnostic grey zone between classic Hodgkin lymphoma (cHL) and some non-Hodgkin lymphoma (NHL), including primary mediastinal B cell lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma.
  • To investigate this, we undertook an expression profiling study of these lymphomas using comparative expressed sequence hybridization.
  • Using this approach, we identified a unique expression profile for all lymphoma types investigated.
  • Moreover, anaplastic lymphoma kinase (ALK)-negative ALCL clustered in a separate branch together with ALCL-like HL.
  • Thus, analysing the neoplastic cells concurrently with their microenvironment, ALK-negative ALCL and ALCL-like HL seem to be related to each other, while cHL constitutes a separate lymphoma entity.
  • [MeSH-major] Hodgkin Disease / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization / methods

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874743.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


48. Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, Oconnor OA, Yahalom J, Zelenetz AD, Moskowitz CH: Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol; 2005 Sep;130(5):691-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
  • Primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathological entity with unclear prognostic factors and optimal treatment approach.
  • Patients received cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone (CHOP)-like therapy, the non-Hodgkin lymphoma (NHL)-15 regimen or upfront autologous stem cell transplantation (ASCT) on Institutional Review Board approved trials or according to the institutional guidelines.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mediastinal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Factor Analysis, Statistical. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Stem Cell Transplantation. Survival Analysis. Transplantation, Autologous

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115124.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5901CA05826-34
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


49. Hasserjian RP, Ströbel P, Marx A: Pathology of thymic tumors. Semin Thorac Cardiovasc Surg; 2005;17(1):2-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of thymic tumors.
  • As the thymus is composed of heterogeneous admixture of lymphoid and epithelial elements, tumors originating in the thymus may be of varied histologic types.
  • Thymomas are the most common thymic tumor in adults.
  • In addition to histologic subtype, tumor stage and resection status are important factors in determining outcome in thymomas.
  • Thymic lymphomas typically occur in younger patients than thymomas.
  • The most common thymic lymphomas are precursor T-lymphoblastic lymphoma, Hodgkin lymphoma, and primary mediastinal large B-cell lymphoma.
  • Thorough histologic sampling and, in some cases, the appropriate use of ancillary studies such as immunohistochemistry, flow cytometry, and molecular studies, are important in proper pathologic evaluation of thymic tumors.
  • [MeSH-major] Carcinoma / pathology. Hodgkin Disease / pathology. Thymoma / pathology. Thymus Gland / pathology. Thymus Neoplasms / classification. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104355.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


50. Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero MD: Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol; 2008 Sep;26(3):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.
  • Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial.
  • We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry.
  • With a median follow-up of 52.5 months, the OS, PFS and DFS at 4 years from diagnosis were, respectively, 84%, 81% and 81% for the first CR patients and 49%, 42% and 82% for the induction failure (PR and refractory) patients.
  • Our experience, with a prolonged follow-up, shows that patients with PMBL presenting at diagnosis with high-risk features or PR response to induction therapy have an encouraging survival with frontline ASCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • [CommentIn] Expert Rev Hematol. 2009 Feb;2(1):31-6 [21082992.001]
  • (PMID = 18432630.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Möller P, Leroy K: Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood; 2009 Aug 6;114(6):1236-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
  • Primary mediastinal B-cell lymphoma (PMBL) is a separate entity of aggressive B-cell lymphoma, characterized by a constitutive activation of janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, also observed in Hodgkin lymphoma.
  • Here, we show that MedB-1 PMBL-derived and L1236 Hodgkin-derived cell lines and 20 of 55 (36%) PMBL cases harbor heterozygous missense mutations in STAT6 DNA binding domain, whereas no mutation was found in 25 diffuse large B-cell lymphoma samples.
  • The mutant STAT6 proteins showed a decreased DNA binding ability in transfected HEK cells, but no decrease in expression of STAT6 canonical target genes was observed in PMBL cases with a mutated STAT6 gene.
  • Although the oncogenic properties of STAT6 mutant proteins remain to be determined, their recurrent selection in PMBL strongly argues for their involvement in the pathogenesis of this aggressive B-cell lymphoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics. Mutation / genetics. Neoplasm Proteins / genetics. STAT6 Transcription Factor / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Male. Protein Structure, Tertiary / genetics. Signal Transduction / genetics

  • HAL archives ouvertes. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2756-61 [12446450.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3478-87 [12646608.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3271-5 [15126369.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1091-9 [15377470.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Cell. 1998 May 29;93(5):827-39 [9630226.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):145-51 [9671298.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):178-87 [10029446.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1939-46 [10377189.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2363-6 [16208407.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2470-3 [16269615.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88 [16540365.001]
  • [Cites] Nat Rev Immunol. 2006 Aug;6(8):573-83 [16868548.001]
  • [Cites] PLoS Genet. 2006 Aug 18;2(8):e131 [16934001.001]
  • [Cites] Haematologica. 2007 Jul;92(7):913-20 [17606441.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1058-62 [17676033.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4367-9 [17878403.001]
  • [Cites] Trends Biochem Sci. 2008 Mar;33(3):122-31 [18291658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2106-10 [18401415.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14255-9 [10747856.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):348-53 [11291070.001]
  • [CommentIn] Blood. 2009 Aug 6;114(6):1133-4 [19661272.001]
  • (PMID = 19423726.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human
  • [Other-IDs] NLM/ HALMS411059; NLM/ PMC2824656
  •  go-up   go-down


52. Coso D, Rey J, Bouabdallah R: [Primary mediastinal B-cell lymphoma]. Rev Pneumol Clin; 2010 Feb;66(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mediastinal B-cell lymphoma].
  • [Transliterated title] Lymphomes B primitifs du médiastin: aspect clinique.
  • Primary mediastinal B-cell lymphoma (PMBL) is a clinicopathological entity among the world health organization classification of lymphoid neoplasms.
  • PMBL often concerns young adults, and the disease remains a localized disease in the majority of cases.
  • The outcome of patients with PMBL is variable and unlike diffuse large cell lymphomas, the international prognostic index seems to be less applicable to such disease.
  • However, high-dose chemotherapy supported by peripheral blood stem cell support is often warranted in poor-prognosis patients.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fluorodeoxyglucose F18. Hematopoietic Stem Cell Transplantation. Humans. Positron-Emission Tomography. Prognosis. Radiotherapy, Adjuvant. Rituximab. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Masson SAS.
  • (PMID = 20207294.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 32
  •  go-up   go-down


53. Banche G, Allizond V, Mandras N, Garzaro M, Cavallo GP, Baldi C, Scutera S, Musso T, Roana J, Tullio V, Carlone NA, Cuffini AM: Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. Int J Immunopathol Pharmacol; 2007 Jan-Mar;20(1):129-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present trial is to evaluate the efficacy of the treatment with an immunostimulating vaccine consisting of a polyvalent mechanical bacterial lysate (PMBL) in the prophylaxis of allergic rhinitis and subsequently to analyze its in vivo effects on immune responses.
  • 41 allergic rhinitis patients were enrolled: 26 patients were randomly assigned to the group for PMBL sublingual treatment and 15 others to the group for placebo treatment.
  • For all 26 patients blood samples were drawn just before (T0) and after 3 months of PMBL treatment (T3) to evaluate plasma IgE levels (total and allergen-specific) and the cytokine production involved in the allergic response (IL-4, IFN-gamma).
  • The results of our study indicate that PMBL is effective in vivo in the reduction or in the elimination of the symptoms in rhinitis subjects during the treatment period in comparison to a non-immunostimulating treatment.
  • PMBL treatment did not affect the serum IgE levels (either total or allergen-specific) and did not induce significant changes in IFN-gamma concentration.
  • In contrast, PMBL therapy may be accompanied, in some patients, by a potential immunomodulating activity by decreasing IL-4 cytokine expression.

  • Genetic Alliance. consumer health - Allergic rhinitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346436.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Bacterial Vaccines; 0 / Cytokines; 0 / RNA, Messenger; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


54. Frank DA: STAT6 in PMBL: pathogenic or passenger? Blood; 2009 Aug 6;114(6):1133-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT6 in PMBL: pathogenic or passenger?

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2009 Aug 6;114(6):1236-42 [19423726.001]
  • (PMID = 19661272.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Barth TF, Möller P: [Mediastinal large B-cell lymphoma]. Pathologe; 2007 Feb;28(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal large B-cell lymphoma].
  • [Transliterated title] Das mediastinale (thymische) grosszellige B-Zell-Lymphom.
  • Mediastinal B-cell lymphoma is a locally highly aggressive tumour which was first described in the early 1980s.
  • The incidence is about 2-3% of all non-Hodgkin's lymphomas.
  • The conceptional evolution of this lymphoma entity was hampered by its low incidence and the broad spectrum of morphological variants present.
  • However, since mediastinal B-cell lymphoma has distinct morphological, immunological, genetic, and clinical features, it has been listed in the revised European-American Classification of Lymphoid Neoplasms (REAL-Classification) since 1994 as a variant of diffuse large B-cell lymphoma.
  • In the World Health Organization classification of malignant lymphomas, mediastinal B-cell lymphoma is now listed with an own disease code (ICD-9679/3).
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Humans. Immunophenotyping. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Neoplasm Staging

  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(1):79-92 [3085342.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):735-41 [7887454.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Int J Cancer. 1989 Jan 15;43(1):10-6 [2783413.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1880-2 [16871282.001]
  • [Cites] Histopathology. 1986 Jun;10(6):589-600 [3525372.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1277-82 [11688462.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2017-25 [8669486.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):676-80 [3923821.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):203-9 [10502317.001]
  • [Cites] Nature. 1997 Jun 26;387(6636):921-4 [9202126.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1280-7 [3263309.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1309-20 [10064597.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2868-76 [12829584.001]
  • [Cites] Blood. 1987 Apr;69(4):1087-95 [3103712.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2479-85 [10561312.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(1):17-21 [2825402.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3072-82 [7579401.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2486-92 [7139540.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3567-75 [10552968.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1646-53 [9193365.001]
  • [Cites] Immunology. 1986 Nov;59(3):411-7 [3491784.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):178-87 [10029446.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):106-13 [10520030.001]
  • [Cites] Blood. 2006 Jul 1;108(1):311-8 [16543468.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Pathol. 2005 Feb;205(3):336-48 [15682441.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jun;31(2):191-5 [11319807.001]
  • [Cites] Eur J Immunol. 1997 Jun;27(6):1398-405 [9209491.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):348-53 [11291070.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):241-7 [10439805.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • (PMID = 17195039.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Iwasaki Y, Takami U, Shinohara Y, Kurita K, Akiyoshi K: Selective biorecognition and preservation of cell function on carbohydrate-immobilized phosphorylcholine polymers. Biomacromolecules; 2007 Sep;8(9):2788-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective biorecognition and preservation of cell function on carbohydrate-immobilized phosphorylcholine polymers.
  • Poly[2-methacryloyloxyethyl phosphorylcholine (MPC)-co-n-butyl methacrylate (BMA)-co-2-lactobionamidoethyl methacrylate (LAMA)] (PMBL) was synthesized and coated on substrates by solvent evaporation.
  • Selective binding of galactose-recognized lectin, RCA120, to a PMBL surface was investigated by measurement of surface plasmon resonance.
  • The binding of RCA120 to the PMBL surface was confirmed by a remarkable change in resonance angle.
  • When a glucose-recognized lectin, concanavalin A, was in contact with PMBL, no change in the resonance angle was observed, and any nonspecific fouling of protein on PMBL was effectively reduced.
  • Cells of the human hepatocellular liver carcinoma cell line (HepG2) having asialoglycoprotein receptors (ASGPRs) were seeded on polymer surfaces.
  • On poly(BMA) (PBMA), many adherent cells were observed and were well-spread with monolayer adhesion, but cell adhesion was reduced on poly(MPC-co-BMA) (PMB).
  • HepG2 adhesion was observed on PMBL because the cell has ASGPRs; the number of cells adhering to the PMBL polymer surfaces increased with an increase in the density of galactose residues on the surface.
  • In contrast, adhesion of NIH-3T3 cells to PMBL was reduced in a manner similar to that on PMB because the NIH-3T3 cells did not have ASGPRs.
  • Cell adhesion to the PMBL surface was well-regulated by ligand-receptor interactions.
  • Furthermore, some of the cells adhering to the PMBL surface had a spheroid form, and similarly shaped spheroids were scattered on the surface.
  • The MPC units in PMBL contribute to make a spheroid formation of HepG2 cells.
  • The amount of albumin secreted from a cell was compared with the chemical structure of the substrate.
  • The spheroid shaped cells cultured on the PMBL surface secreted much more albumin than did the spreading cells that adhered to the PBMA.
  • In conclusion, the biomembrane mimetic carbohydrate-immobilized phosphorylcholine polymers produced a suitable surface for biorecognition and preservation of cell function.
  • [MeSH-minor] Albumins / metabolism. Animals. Cell Culture Techniques. Cell Line. Cell Line, Tumor. Hepatocytes / physiology. Humans. Lectins / chemistry. Mice. NIH 3T3 Cells. Protein Binding

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663529.001).
  • [ISSN] 1525-7797
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / Carbohydrates; 0 / Lectins; 0 / Polymers; 107-73-3 / Phosphorylcholine
  •  go-up   go-down


57. Staudt LM, Dave S: The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol; 2005;87:163-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene expression profiling provides a quantitative molecular framework for the study of human lymphomas.
  • Diffuse large B-cell lymphoma (DLBCL), for example, consists of three gene expression subgroups, termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL).
  • These DLBCL subgroups arise from different stages of normal B-cell differentiation, utilize distinct oncogenic mechanisms, and differ in their ability to be cured by chemotherapy.
  • ABC DLBCL and PMBL depend upon constitutive activation of the NF-kappaB pathway for their survival but GCB DLBCL does not, demonstrating that this pathway is a potential therapeutic target for certain DLBCL subgroups.
  • In DLBCL, mantle cell lymphoma, and follicular lymphoma, gene expression profiling has also been used to create gene expression-based models of survival, which have identified the biological characteristics of the tumors that influence their clinical behavior.
  • In mantle cell lymphoma, the length of survival following diagnosis is primarily influenced by the tumor proliferation rate, which can be quantitatively measured by a proliferation gene expression "signature."
  • Based on this accurate measure, the proliferation rate can now be viewed as an integration of several oncogenic lesions that each increase progression from the G1 to the S phase of the cell cycle.
  • In DLBCL and follicular lymphoma, gene expression profiling has revealed that the molecular characteristics of non-malignant tumor-infiltrating immune cells have a major influence on the length of survival.
  • The implications of these insights for the diagnosis and treatment of non-Hodgkin lymphomas are discussed.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1365-9 [10581077.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:23-7 [10707774.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5998-6004 [10820283.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1987-96 [10854221.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10209-13 [10954754.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1027-34 [11015443.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):7903-13 [11027261.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5462-71 [11067898.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):331-40 [11100880.001]
  • [Cites] Blood. 2001 Jan 1;97(1):101-6 [11133748.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:71-8 [11232339.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):261-8 [11224527.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):526-32 [11101876.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2409-12 [11289106.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1099-103 [11323673.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):925-9 [11420464.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):300-7 [11460154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9654-9 [11481442.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):926-34 [11567221.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2762-70 [11675349.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1517-26 [11861263.001]
  • [Cites] Immunity. 2002 Jul;17(1):51-62 [12150891.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):103-12 [12204530.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):11-20 [12270057.001]
  • [Cites] J Mol Med (Berl). 2003 May;81(5):281-7 [12721664.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1721-30 [12810690.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):135-44 [12819018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Semin Cancer Biol. 2003 Jun;13(3):191-202 [12959350.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38980-90 [12860980.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):747-52 [14514777.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Immunity. 2003 Oct;19(4):607-20 [14563324.001]
  • [Cites] Nucleic Acids Res. 2003 Nov 1;31(21):6148-56 [14576301.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):191-9 [14998494.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4251-8 [14976040.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S5-12 [15202519.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36698-707 [15199070.001]
  • [Cites] Immunity. 2004 Jul;21(1):81-93 [15345222.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2105-10 [15370257.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):712-7 [15361884.001]
  • [Cites] Nature. 1982 Sep 2;299(5878):65-7 [7110326.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Histopathology. 1986 Apr;10(4):379-90 [2423430.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):81-9 [2069139.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):4846-53 [1833629.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1401-6 [1535701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4 [1495966.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):885-95 [1415907.001]
  • [Cites] Immunology. 1992 Dec;77(4):621-3 [1337336.001]
  • [Cites] Leukemia. 1993 Mar;7(3):398-403 [7680400.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Immunol Res. 1993;12(3):213-32 [8288943.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3689-96 [8204893.001]
  • [Cites] Oncogene. 1994 Jul;9(7):1925-9 [8208539.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1203-11 [7981148.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1833-40 [7753558.001]
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Am J Pathol. 1995 Aug;147(2):405-11 [7639334.001]
  • [Cites] Cell. 1995 Aug 25;82(4):621-30 [7664341.001]
  • [Cites] Biochim Biophys Acta. 1996 Feb 7;1305(1-2):39-43 [8605247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5500-10 [9710634.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):943-53 [10023670.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1961;26:389-401 [14475415.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Mar 27;220(3):911-5 [8607866.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):393-401 [8627152.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):971-7 [8642300.001]
  • [Cites] Oncogene. 1996 Jun 6;12(11):2331-42 [8649773.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1269-74 [8648383.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]
  • [Cites] J Immunol. 1996 Jul 1;157(1):81-6 [8683159.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6947-52 [8692924.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1359-64 [8695854.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):627-37 [8760816.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20231-4 [8702752.001]
  • [Cites] Blood. 1997 Jan 1;89(1):272-80 [8978301.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2507-12 [9122225.001]
  • [Cites] Int Immunol. 1997 Mar;9(3):407-14 [9088979.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Science. 1997 Apr 25;276(5312):596-9 [9110979.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Eur J Immunol. 1997 Jun;27(6):1398-405 [9209491.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7 [9380707.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4608-14 [9377576.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2977-84 [9531609.001]
  • [Cites] Oncogene. 1998 Apr 23;16(16):2131-9 [9572494.001]
  • [Cites] Nucleic Acids Res. 1998 Jun 15;26(12):2899-907 [9611234.001]
  • [Cites] Genes Dev. 1998 Jul 1;12(13):1953-61 [9649500.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1804-18 [11865059.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2562-8 [11895794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9 [11983876.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):333-8 [12042708.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(13):4771-80 [12052884.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):611-8 [12087419.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):2991-3003 [12464630.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Blood. 2003 Jan 15;101(2):433-40 [12509382.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5205-13 [12435740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2639-44 [12604779.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12563-73 [12529326.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3181-7 [12515730.001]
  • [Cites] Cell. 2003 Apr 18;113(2):207-19 [12705869.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 2;304(2):393-8 [12711328.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Nat Med. 2003 May;9(5):562-7 [12704383.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4464-71 [12531790.001]
  • (PMID = 16102574.001).
  • [ISSN] 0065-2776
  • [Journal-full-title] Advances in immunology
  • [ISO-abbreviation] Adv. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC004024-18
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 165
  • [Other-IDs] NLM/ NIHMS5150; NLM/ PMC1351148
  •  go-up   go-down


58. Dzhumabaeva BT, Kremenetskaia AM, Gotman LN, Shavlokhov VS, Kaplanskaia IB, Kravchenko SK, Vishnevskaia ES, Gemdzhian EG, Frank GA: [Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma]. Ter Arkh; 2005;77(8):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
  • AIM: To evaluate efficacy of treatment of primary mediastinal B-cell lymphosarcoma (PMBLS).
  • Group 3 (n = 36)--2 courses of CHOP and 2-3 courses of ESHAP or 3 courses of DexaBEAM, surgical removal of residual mediastinal tumor (RMT), RT.
  • CONCLUSION: CHOP program is ineffective in PMBLS.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / surgery. Mediastinal Neoplasms / radiotherapy. Mediastinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206611.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MACOP-B protocol
  •  go-up   go-down


59. Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P, Alonso MA, Pohlman B: MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol; 2006 May;125(5):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
  • Classical Hodgkin lymphoma (cHL) and mediastinal (thymic) large B-cell lymphoma (MLBL) have clinical, histopathologic, and molecular genetic similarities.
  • Expression correlated with nodular sclerosis subtype, and within this subtype, with grade 2 histology.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Membrane Transport Proteins / metabolism. Myelin Proteins / metabolism. Proteolipids / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / therapy. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707382.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  •  go-up   go-down


60. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M: Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Jul;49(7):1329-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma (PMLCL) is an aggressive non-Hodgkin lymphoma with distinct clinical and gene expression profiles.
  • Outcomes of salvage chemotherapy and autologous stem cell transplantation (ASCT) for relapsed or refractory disease (RR) have not been well characterised.
  • We retrospectively identified 180 consecutive RR patients (37 PMLCL and a control group of 143 DLBCL) that underwent salvage chemotherapy.
  • The overall response rate (ORR) to salvage chemotherapy (25% vs. 48%, p = 0.01) and 2-year OS after diagnosis of RR disease (15% vs. 34%, p = 0.018) was inferior in PMLCL patients.
  • The 2-year post-ASCT OS (67% PMLCL vs. 53%, p = 0.78) and PFS (57% PMLCL vs. 36%, p = 0.64) were similar.
  • RR PMLCL had an inferior ORR and survival compared with DLBCL but chemosensitive PMLCL and DLBCL patients have similar outcomes post-ASCT.
  • Strategies for PMLCL should focus on identifying poor risk patients to test novel induction and salvage strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy. Salvage Therapy / methods


61. Ríos A, Torres J, Roca MJ, Galindo PJ, Alonso JL, Parrilla P: [Primary thymic lymphomas]. Rev Clin Esp; 2006 Jul-Aug;206(7):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary thymic lymphomas].
  • [Transliterated title] Linfomas primarios del timo.
  • INTRODUCTION: Primary thymic lymphomas (PTLs) are uncommon, and their prognosis is linked with early treatment.
  • MATERIAL AND METHODS: Ten LPTs--four Hodgkin's and six non-Hodgkin's (4 primary mediastinal B lymphomas [PMBLs] and 2 lymphoblastic T lymphomas [LTLs]--were reviewed.
  • RESULTS: The initial diagnostic suspicion in the Hodgkin's lymphomas was thymoma in two cases and lymphoma in the other 2.
  • The non-Hodgkin's lymphomas had large tumors and short evolution.
  • CONCLUSIONS: In a patient with thymic tumour with a preoperative or intraoperative study suspected of having a lymphoma, it is necessary to do a biopsy and not resective surgery, to avoid unnecessary resections and morbidity.
  • PTLs are uncommon but aggressive, principally the non-Hodgkin's lymphomas.
  • [MeSH-major] Hodgkin Disease / radiography. Lymphoma, Non-Hodgkin / radiography. Thymus Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831379.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL: No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma. Diagn Mol Pathol; 2009 Sep;18(3):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma.
  • Recently, our work comparing gene expression signatures of primary mediastinal large B-cell lymphomas (PMLBCL) versus nodal diffuse large B-cell lymphomas revealed a relative increase in JAK2 transcripts in the former, suggesting a role for increased JAK2 signaling in a subset of these tumors.
  • Analysis using cell lines derived from PMLBCLs (n = 1) and from the molecularly similar classic Hodgkin lymphoma (n = 4) also failed to reveal involvement of a mutant JAK2 allele.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1986 Mar;10(3):176-91 [3953939.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Nature. 1997 Jun 26;387(6636):917-21 [9202125.001]
  • [Cites] Nature. 1997 Jun 26;387(6636):921-4 [9202126.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Leukemia. 2006 Jan;20(1):157-8 [16331280.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] N Engl J Med. 2007 Feb 1;356(5):459-68 [17267906.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1686-9 [17984312.001]
  • [Cites] J Leukoc Biol. 1999 Oct;66(4):588-92 [10534114.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):951-6 [10551323.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nat Genet. 2001 May;28(1):29-35 [11326271.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B49-53 [11757707.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):730-9 [2788371.001]
  • (PMID = 19704259.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092625-08; United States / NCI NIH HHS / CA / P01 CA092625; United States / NCI NIH HHS / CA / P01 CA092625-08; United States / NCI NIH HHS / CA / P01CA092625-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ NIHMS80972; NLM/ PMC2732663
  •  go-up   go-down


63. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM: Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med; 2007 Mar 19;204(3):633-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
  • To elucidate the mechanisms underlying chromosomal translocations in diffuse large B cell lymphoma (DLBCL), we investigated the nature and extent of immunoglobulin class switch recombination (CSR) in these tumors.
  • We used Southern blotting to detect legitimate and illegitimate CSR events in tumor samples of the activated B cell-like (ABC), germinal center B cell-like (GCB), and primary mediastinal B cell lymphoma (PMBL) subgroups of DLBCL.
  • The frequency of legitimate CSR was lower in ABC DLBCL than in GCB DLBCL and PMBL.
  • In contrast, ABC DLBCL had a higher frequency of internal deletions within the switch mu (Smu) region compared with GCB DLBCL and PMBL.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2007 Jan;37(1):235-9 [17183606.001]
  • [Cites] Immunity. 2006 Aug;25(2):225-36 [16919487.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1032-8 [10648419.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Cell. 2000 Sep 1;102(5):565-75 [11007475.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:71-8 [11232339.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] Nature. 2001 Dec 6;414(6864):660-5 [11740565.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Trends Immunol. 2002 Jan;23(1):31-9 [11801452.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1301-6 [11847344.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9984-9 [12114543.001]
  • [Cites] Immunity. 2002 Jul;17(1):51-62 [12150891.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):413-20 [12163366.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1015-23 [12393575.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1767-78 [12810694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Nat Immunol. 2004 May;5(5):481-7 [15077110.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):541-52 [15229473.001]
  • [Cites] Cell. 2004 Aug 20;118(4):431-8 [15315756.001]
  • [Cites] Immunity. 2004 Jul;21(1):81-93 [15345222.001]
  • [Cites] Blood. 1996 Jul 15;88(2):674-81 [8695815.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):203-14 [8691135.001]
  • [Cites] Blood. 1996 Aug 1;88(3):985-94 [8704258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 [8943038.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7118-29 [9384589.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]
  • [Cites] J Exp Med. 2004 Nov 1;200(9):1111-21 [15504820.001]
  • [Cites] J Exp Med. 2004 Nov 1;200(9):1103-10 [15520243.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3318-25 [15304391.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2026-31 [15496980.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):655-61 [15970938.001]
  • [Cites] Adv Immunol. 2005;87:163-208 [16102574.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):561-8 [16103411.001]
  • [Cites] Mol Cell. 2006 Jan 20;21(2):201-14 [16427010.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Nature. 2006 Mar 2;440(7080):105-9 [16400328.001]
  • [Cites] Curr Opin Immunol. 2006 Apr;18(2):164-74 [16464563.001]
  • [Cites] Blood. 2006 May 15;107(10):4090-100 [16424392.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33 [10618400.001]
  • (PMID = 17353367.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114778-01; United States / NCI NIH HHS / CA / U01 CA084967; United States / NCI NIH HHS / CA / U01 CA114778-01; United States / NCI NIH HHS / CA / U01-CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2137913
  •  go-up   go-down


64. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Küppers R: TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med; 2009 May 11;206(5):981-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.
  • Proliferation and survival of Hodgkin and Reed/Sternberg (HRS) cells, the malignant cells of classical Hodgkin lymphoma (cHL), are dependent on constitutive activation of nuclear factor kappaB (NF-kappaB).
  • To determine whether A20 contributes to the pathogenesis of cHL, we sequenced TNFAIP3, encoding A20, in HL cell lines and laser-microdissected HRS cells from cHL biopsies.
  • Reconstitution of wild-type TNFAIP3 in A20-deficient cHL cell lines revealed a significant decrease in transcripts of selected NF-kappaB target genes and caused cytotoxicity.
  • Extending the mutation analysis to primary mediastinal B cell lymphoma (PMBL), another lymphoma with constitutive NF-kappaB activity, revealed destructive mutations in 5 out of 14 PMBLs (36%).
  • This report identifies TNFAIP3 (A20), a key regulator of NF-kappaB activity, as a novel tumor suppressor gene in cHL and PMBL.
  • [MeSH-major] Chromosome Deletion. Genes, Tumor Suppressor. Hodgkin Disease / genetics. Intracellular Signaling Peptides and Proteins / genetics. Lymphoma, B-Cell / genetics. Mutation. Nuclear Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Transposable Elements. DNA-Binding Proteins. Epstein-Barr Virus Infections / genetics. Frameshift Mutation. Humans. Mutation, Missense. Polymorphism, Single Nucleotide. Transcription, Genetic

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):52-8 [10564586.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] Science. 2000 Sep 29;289(5488):2350-4 [11009421.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):413-20 [12163366.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] J Pathol. 2003 Jun;200(2):229-39 [12754742.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):589-94 [15064769.001]
  • [Cites] Nature. 2004 Aug 5;430(7000):694-9 [15258597.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1052-60 [15334086.001]
  • [Cites] EMBO J. 1995 Jun 15;14(12):2876-83 [7796813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6721-5 [8692885.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):310-3 [9087572.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1392-9 [15870177.001]
  • [Cites] Blood. 2006 Jan 15;107(2):844-5 [16401828.001]
  • [Cites] Nat Cell Biol. 2006 Apr;8(4):398-406 [16547522.001]
  • [Cites] Mol Cell. 2006 Apr 21;22(2):245-57 [16603398.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6831-43 [17072331.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4777-85 [17699855.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1090-7 [17823928.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):1-7 [17886247.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2463-9 [17728785.001]
  • [Cites] Cytogenet Genome Res. 2007;119(3-4):204-10 [18253030.001]
  • [Cites] Cell. 2008 Feb 8;132(3):344-62 [18267068.001]
  • [Cites] Nat Immunol. 2008 Mar;9(3):263-71 [18223652.001]
  • [Cites] Immunity. 2008 Mar;28(3):381-90 [18342009.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1318-26 [18641027.001]
  • [Cites] Br J Haematol. 2008 Sep;142(6):916-24 [18671701.001]
  • [Cites] J Pathol. 2009 Feb;217(3):420-30 [19006194.001]
  • [Cites] Blood. 2009 May 14;113(20):4918-21 [19258598.001]
  • (PMID = 19380639.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; EC 6.3.2.19 / TNFAIP3 protein, human
  • [Other-IDs] NLM/ PMC2715030
  •  go-up   go-down


65. Savage KJ: Primary mediastinal large B-cell lymphoma. Oncologist; 2006 May;11(5):488-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma represents a distinct entity with unique clinicopathologic features and a molecular gene-expression signature reminiscent of nodular sclerosis subtype of classical Hodgkin's lymphoma.
  • Recent studies, including those using a refined molecular signature, suggest that the outcome is more favorable than that of diffuse large B-cell lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720849.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 47
  •  go-up   go-down


66. Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M: Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma; 2009 Oct;9(5):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
  • BACKGROUND: Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL).
  • Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk diffuse large B-cell lymphoma.
  • PATIENTS AND METHODS: Retrospectively, between February 2002 and July 2006, 45 previously untreated patients with PMLBCL were treated with a combination of a third-generation chemotherapy regimen (MACOP-B or VACOP-B), concurrent rituximab, and mediastinal radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858058.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MACOP-B protocol; VACOP-B protocol
  •  go-up   go-down


67. Arai H, Iso H, Arai Y, Tadokoro J, Nakamura Y, Yamagata T, Mitani K: [Mediastinal large B-cell lymphoma associated with systemic sclerosis]. Rinsho Ketsueki; 2009 Feb;50(2):97-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal large B-cell lymphoma associated with systemic sclerosis].
  • Malignant lymphoma (ML) is frequently associated with several forms of collagen diseases such as Sjören syndrome, systemic lupus erythematodes, and rheumatoid arthritis.
  • Here we report an SSc patient who developed mediastinal (thymic) large B-cell lymphoma (MLBCL).
  • One year after the diagnosis, chest computed tomography-scan demonstrated thymic tumor in the anterior mediastinum.
  • Thymectomy was performed, and a pathohistological diagnosis of MLBCL was established.
  • The patient was treated with 6 courses of CHOP regimen, resulting in complete remission of lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / etiology. Scleroderma, Systemic / complications. Thymus Neoplasms / etiology


68. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM: Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol; 2006 Jan;17(1):123-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
  • BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinico-pathological subtype of diffuse large B-cell lymphoma (DLBCL).
  • PATIENTS AND METHODS: The British Columbia Cancer Agency lymphoma database was searched and records reviewed to identify those patients presenting with a prominent mediastinal mass and considered to be PMBCL based on the current REAL/WHO classifications.
  • Patients were treated based on era-specific BCCA guidelines (1980-1992 MACOPB/VACOPB; 1992-2001 CHOP-type; 2001-present CHOP-R).
  • The median age was 37 years (range 13-82) and the majority had stage I/II (74%), bulky mediastinal disease (75%).
  • Five-year OS in patients < 65 years old treated with MACOPB/VACOPB, CHOP-R and CHOP-type was 87%, 81% and 71% respectively (P = 0.048).
  • In pair-wise survival comparisons, only MACOPB/VACOPB and CHOP-type treated patients were significantly different (P = 0.016).
  • In Cox multiple regression analysis, poor performance status remained the only predictor of survival, with treatment received demonstrating a trend to worse outcome for patients treated with CHOP-type regimens (P = 0.09).
  • Dose-intensified chemotherapy with MACOPB or VACOPB demonstrated a trend to superior outcome over CHOP-type chemotherapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236753.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Brien G, Trescol-Biemont MC, Bonnefoy-Bérard N: Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene; 2007 Aug 23;26(39):5828-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
  • Elevated expression of the antiapoptotic protein Bfl-1 (A1) was previously reported in several cancer cell lines.
  • Recently, molecular profiling of large B-cell lymphoma identified Bfl-1 as a gene signature in 'OxPhos' diffuse large B-cell lymphoma subtype and in primary mediastinal large B-cell lymphoma, suggesting that in addition to Bcl-2, Bcl-xL and Mcl-1, Bfl-1 may be a relevant target in the design of new strategies for cancer therapy.
  • Using short hairpin RNA strategy, we show here that Bfl-1 silencing in one lymphoblastoid B-cell line and in two diffuse large B-cell lymphoma cell lines potently induces their apoptosis and sensitizes those cell lines to anti-CD20 (Rituximab)-mediated cell death as well as to apoptosis induced by chemotherapeutic molecules such as doxorubicin, vincristine, cisplatin and fludarabine.
  • These results demonstrate for the first time that Bfl-1 is an essential protein for survival of malignant B cells and suggest Bfl-1 may represent a potential target for future drug development against B cell lymphoma.
  • [MeSH-major] Apoptosis / drug effects. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / physiology. Lymphoma, B-Cell / pathology. Proto-Oncogene Proteins c-bcl-2 / genetics

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353899.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / BCL2-related protein A1; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; EC 3.4.22.- / Caspases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS: Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol; 2010 Apr;91(3):456-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.
  • The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL).
  • However, the impact of rituximab (R-CHOP) is still not determined in primary mediastinal large B-cell lymphoma (PMBCL), a subtype of DLBCL, especially in Asian patients.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Mediastinal Neoplasms / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):139-46 [10512171.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Adv Anat Pathol. 2004 Sep;11(5):227-38 [15322489.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):465-71 [15239397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):823-9 [17379431.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):691-9 [16115124.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1280-7 [3263309.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]
  • [Cites] Blood. 1999 Nov 15;94(10 ):3289-93 [10552937.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):784-90 [10071267.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1364-71 [18603558.001]
  • [Cites] Haematologica. 2001 Feb;86(2):187-91 [11224489.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1646-53 [9193365.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1258-64 [12495899.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):877-88 [8669537.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):372-6 [14735179.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 20198460.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


71. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res; 2009 Sep 1;15(17):5494-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
  • PURPOSE: Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes.
  • For a group of seven primary mediastinal large B-cell lymphoma, the new algorithm is a better prognostic classifier (all "GCB") than the Hans' algorithm (two GCB, five non-GCB).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Immunohistochemistry / methods. Lymphoma, Large B-Cell, Diffuse / classification


72. Macchi A, Vecchia LD: Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections. Arzneimittelforschung; 2005;55(5):276-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first group received, by sublingual route, Ismigen, a new immunostimulating lysate (Polivalent Mechanical Bacterial Lysate, PMBL) obtained by mechanical lysis of 48 billion bacteria commonly responsible for upper respiratory tract infections; the second group received an oral immunostimulating lysate (CLBL) obtained by chemical lysis of 36 billion bacteria.
  • One tablet a day of PMBL was given to the first group for the first ten days during three consecutive months; the patients of the second group received one capsule a day of CLBL with the same treatment schedule.
  • The primary end point was the number of acute upper respiratory tract infections (URTIs) that occurred during the three months of treatment and three months of follow-up.
  • During the treatment period the mean number (+/- SD) of URTIs per patient was 0.34 (0.48) in the PMBL group, 1.0 (0.83) and 1.23 (0.77) in the CLBL and Control NT groups, respectively.
  • Results of PMBL treatment were significantly better (p < 0.05) than the results in the other two groups; CLBL was not significantly different from the control group.
  • In the three months of follow-up, the mean number (+/- SD) of URTIs per patient was: 0.42 (0.55) in the PMBL group, 0.92 (0.67) in the CLBL group, and 1.55 (0.88) in the Control NT group.
  • The PMBL group was significantly better than the other two (p < 0.05).
  • During the 6-month study, significantly more patients of the PMBL group remained free from respiratory infections in comparison to the other two groups.
  • As regards other secondary end points (duration of infectious episodes and number of working days lost), the mean values of the PMBL group were statistically significantly lower than those of the other two groups, in both the treatment and follow-up periods.
  • No PMBL treated patient needed concomitant administration of an antibiotic, while 9 patients of the CLBL group received such treatment (p < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960427.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Bacterial Agents; 0 / Bacterial Vaccines
  •  go-up   go-down


73. Kambayashi T, Ono N, Terada Y: [Non-Hodgkin malignant lymphoma of rib origin: report of a case]. Kyobu Geka; 2005 Dec;58(13):1177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin malignant lymphoma of rib origin: report of a case].
  • There were no abnormal findings in the abdomen, lung, mediastinum or bone except the left 8th rib.
  • The histological diagnosis was primary non-Hodgkin lymphoma (diffuse, medium-sized to large B-cell lymphoma).
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Ribs

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359022.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


74. Ioannou S, Vlahadami I, Voulgarelis M: Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma. Leuk Res; 2010 Jan;34(1):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma.
  • [MeSH-major] Bone Marrow / pathology. Embolism, Fat / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Spinal Cord Compression / pathology

  • Genetic Alliance. consumer health - Embolism.
  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540591.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


75. Hoeller S, Zihler D, Zlobec I, Obermann EC, Pileri SA, Dirnhofer S, Tzankov A: BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma. Histopathology; 2010 Jan;56(2):217-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
  • AIMS: To clarify which immunohistochemical markers could be helpful in distinguishing between classical Hodgkin's lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL) to more narrowly define 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and cHL'.
  • CONCLUSIONS: The use of at least three of the most accurate immunohistochemical markers, cyclin E, CD79a and BOB.1, may be helpful in the differential diagnosis of cHL and PMBCL.
  • [MeSH-major] Antigens, CD79 / analysis. Biomarkers, Tumor. Cyclin E / analysis. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Trans-Activators / analysis
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Diagnosis, Differential. Humans. Immunohistochemistry. Predictive Value of Tests. ROC Curve

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102401.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD79; 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / POU2AF1 protein, human; 0 / Trans-Activators
  •  go-up   go-down


76. Lau G: Post-anaesthetic maternal death in a patient with mediastinal large B-cell lymphoma: a case report. Med Sci Law; 2007 Jan;47(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-anaesthetic maternal death in a patient with mediastinal large B-cell lymphoma: a case report.
  • Autopsy demonstrated the presence of a large mediastinal tumour, whose existence was apparently unsuspected preoperatively, encasing the ascending thoracic aorta, aortic arch and the proximal segments of the brachiocephalic and subclavian arteries, and causing extrinsic airway compression.
  • Subsequent microscopic examination showed histological and immunohistochemical features of a mediastinal large B-cell lymphoma.
  • It is thought that the mechanical effects exerted by the advanced mediastinal tumour upon the airways and the thoracic cage, coupled with the pathophysiological effects of general anaesthesia on respiratory movement and airway patency, had led to the patient's unfortunate demise in early pregnancy.
  • [MeSH-major] Anesthesia. Lymphoma, B-Cell / pathology. Maternal Mortality. Mediastinal Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345895.001).
  • [ISSN] 0025-8024
  • [Journal-full-title] Medicine, science, and the law
  • [ISO-abbreviation] Med Sci Law
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Renné C, Willenbrock K, Martin-Subero JI, Hinsch N, Döring C, Tiacci E, Klapper W, Möller P, Küppers R, Hansmann ML, Siebert R, Bräuninger A: High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia; 2007 Apr;21(4):780-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma.
  • Mediastinal large B-cell (MBL) and classical Hodgkin lymphoma (HL) have several pathogenic mechanisms in common.
  • Indeed, MBL and HL were the only B-cell lymphomas where elevated cellular phospho-tyrosine contents were typical features.
  • Among the intracellular pathways frequently triggered by TKs, the PI3K/AKT pathway was activated in about 40% of MBLs and essential for survival of MBL cell lines, whereas the RAF/mitogen-activated protein kinase pathway seemed to be inhibited.
  • No activating mutations were detected in the three TKs in MBL cell lines and primary cases.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. Lymphoma, B-Cell / genetics. Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Enzyme Activation. Gene Expression Regulation, Enzymologic. Humans. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / genetics


78. Quintanilla-Martinez L, de Jong D, de Mascarel A, Hsi ED, Kluin P, Natkunam Y, Parrens M, Pileri S, Ott G: Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematop; 2009;2(4):211-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.
  • The term "gray-zone" lymphoma has been used to denote a group of lymphomas with overlapping histological, biological, and clinical features between various types of lymphomas.
  • It has been used in the context of Hodgkin lymphomas (HL) and non-Hodgkin lymphomas (NHL), including classical HL (CHL), and primary mediastinal large B cell lymphoma, cases with overlapping features between nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B cell lymphoma, CHL, and Epstein-Barr-virus-positive lymphoproliferative disorders, and peripheral T cell lymphomas simulating CHL.
  • A second group of gray-zone lymphomas includes B cell NHL with intermediate features between diffuse large B cell lymphoma and classical Burkitt lymphoma.
  • In order to review controversial issues in gray-zone lymphomas, a joint Workshop of the European Association for Hematopathology and the Society for Hematopathology was held in Bordeaux, France, in September 2008.
  • This Workshop summary is focused on the most controversial aspects of gray-zone lymphomas and describes the panel's proposals regarding diagnostic criteria, terminology, and new prognostic and diagnostic parameters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2008 Jun;99(6):1085-91 [18429953.001]
  • [Cites] Am J Clin Pathol. 2009 Apr;131(4):511-5 [19289586.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Ther Clin Risk Manag. 2009 Feb;5(1):187-207 [19436622.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Hum Pathol. 1972 Dec;3(4):457-558 [4638966.001]
  • [Cites] Am J Med. 1980 Apr;68(4):509-14 [6892753.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:7-11 [8172822.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):193-201 [8554109.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2445-50 [9310496.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):241-7 [10439805.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3567-75 [10552968.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):223-8 [10757332.001]
  • [Cites] Blood. 2000 May 15;95(10):3020-4 [10807764.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1889-99 [10961891.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):293-300 [11350613.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):679-86 [15105659.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S21-6 [15202521.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] Histopathology. 2004 Dec;45(6):619-24 [15569053.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):389-95 [15725472.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):199-205 [15813847.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):45-52 [16007868.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Dec;17(8):636-8 [16372490.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):585-92 [16699312.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):776-82 [16707382.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1885-93 [17065002.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):106-12 [17197926.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):44-53 [17555446.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1090-7 [17823928.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1605-14 [17895764.001]
  • [Cites] Blood. 2008 Jan 1;111(1):351-8 [17898315.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):981-91 [18024324.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Apr;129(4):630-8 [18343791.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4805-15 [18354204.001]
  • [Cites] Eur J Haematol. 2008 Aug;81(2):154-6 [18462255.001]
  • [Cites] Histopathology. 2008 Jun;52(7):900-3 [18494615.001]
  • [Cites] Int J Surg Pathol. 2009 Apr;17(2):163-6 [18508845.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1252-7 [18594468.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2226-9 [18754028.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2629-36 [19075188.001]
  • [Cites] Hum Pathol. 2009 May;40(5):653-61 [19144386.001]
  • [Cites] Blood. 2009 May 7;113(19):4771-9 [19211934.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):335-40 [19255922.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1123-30 [9327746.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1133-8 [9426333.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):178-87 [10029446.001]
  • [Cites] Semin Diagn Pathol. 1992 Nov;9(4):297-303 [1480852.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Am J Med. 1985 May;78(5):885-90 [2859806.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(1):79-92 [3085342.001]
  • [Cites] Blood. 1987 Apr;69(4):1087-95 [3103712.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):122-32 [3812872.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10(3):176-91 [3953939.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1458-66 [12409722.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1861-7 [12414532.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1172-80 [12429796.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3753-8 [12881319.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1346-56 [14508396.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • (PMID = 20309430.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798939
  • [Keywords] NOTNLM ; European Association for Hematopathology / Gray zone lymphoma / Society for Hematopathology / Workshop
  •  go-up   go-down


79. Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA: Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. Blood; 2006 Jan 15;107(2):844-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. I-kappa B Proteins / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Mediastinal Neoplasms / genetics. Mutation / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401828.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


80. Oura H, Watanabe Y, Sawada T, Handa M, Tomichi N: [Surgical approach for histopathological determination of anterior mediastinal malignant lymphoma]. Kyobu Geka; 2008 Aug;61(9):754-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical approach for histopathological determination of anterior mediastinal malignant lymphoma].
  • In a retrospective review of all patients who admitted our hospital between January 1992 and December 2006, we identified 9 with anterior mediastinal malignant lymphoma.
  • They represented 6.8% of the 133 patients with mediastinal tumor.
  • Histology revealed 3 cases of primary mediastinal large B-cell lymphoma, 2 of Hodgkin lymphoma, 2 of precursor T-lymphoblastic lymphoma and 2 of thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma.
  • Careful attention should be paid to the relatively high incidence of malignant lymphoma in the anterior mediastinal tumors.
  • It is highly important to differentiate of malignant lymphoma from other diseases that shape anterior mediastinal tumor to avoid unnecessary operation.
  • Early and accurate diagnosis of these tumors is also important because some of these patients require immediate treatment by hematology specialists.
  • [MeSH-major] Lymphoma / pathology. Mediastinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697455.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Rajagopalan R, Salvi VP, Jensenius JC, Rawal N: New insights on the structural/functional properties of recombinant human mannan-binding lectin and its variants. Immunol Lett; 2009 Apr 27;123(2):114-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • But recent studies have shown the presence of large oligomers of MBL (approximately 450 kDa) in serum of individuals with variant MBL alleles.
  • In the present study, structural/functional properties of recombinant forms of wild type MBL (rMBL/A) and its three structural variants, rMBL/B, C, and D generated in insect cells were examined.
  • Comparison of rMBL/A to MBL purified from plasma (pMBL/A) indicated 8- and 24-fold weaker binding to mannan by BIAcore analysis and ELISA and about 5-fold lesser efficiency in activating complement.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428558.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-073804
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Mannose-Binding Lectin; 0 / Recombinant Proteins
  •  go-up   go-down


82. Kelemen K, Cao W, Peterson LC, Evens AM, Variakojis D: Primary mediastinal large B-cell lymphoma in HIV: report of two cases. J Hematop; 2009 Mar;2(1):45-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal large B-cell lymphoma in HIV: report of two cases.
  • Primary mediastinal large B cell lymphoma (PMLBCL) is a subtype of diffuse large B cell lymphoma arising in the mediastinum with distinctive clinical and morphological features.
  • Though diffuse large B cell lymphoma is one of the most common non-Hodgkin lymphoma associated with AIDS, there are no data available regarding the association of HIV and PMLBCL.
  • In both cases, PMLBCL presented in a setting of low CD4 T-cell count as rapidly enlarging mediastinal mass.
  • The morphologic and immunophenotypic findings are characteristic of PMLBCL.
  • One of the two patients, a 25-year-old woman who had localized disease and evidence of Epstein-Barr virus in lymphoma cells, did not respond to chemotherapy and died of disease progression 5 months after diagnosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):44-54 [8465656.001]
  • [Cites] J Pathol. 1992 Aug;167(4):381-4 [1328576.001]
  • [Cites] Blood. 1991 Aug 1;78(3):780-8 [1713514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Blood. 2007 Aug 1;110(3):972-8 [17400912.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Med Sci. 2005 Mar;329(3):136-8 [15767818.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):1135-48 [8880201.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):235-43 [7794745.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 19669223.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2713493
  •  go-up   go-down


83. Minami J, Dobashi N, Asai O, Yano S, Osawa H, Takei Y, Yahagi Y, Takahara S, Ogasawara Y, Yamaguchi Y, Kobayashi T, Morikawa N, Nikaido T, Aiba K, Usui N: Two cases of mediastinal gray zone lymphoma. J Clin Exp Hematop; 2010;50(2):143-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of mediastinal gray zone lymphoma.
  • Mediastinal gray zone lymphoma (MGZL) represents a range of tumors possessing characteristics of both nodular sclerosis classical Hodgkin lymphoma (NSHL) and mediastinal large B-cell lymphoma (MLBCL).
  • Both patients had a mediastinal mass, were initially diagnosed with NSHL and exhibited resistance to first-line chemotherapy.
  • In patient 2, the tumor was a composite lymphoma with both NSHL and MLBCL components.
  • Both the patients received high-dose chemotherapy followed by autologous peripheral-blood stem-cell transplantation.
  • [MeSH-major] Lymphoma / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Peripheral Blood Stem Cell Transplantation. Radiotherapy. Young Adult

  • Genetic Alliance. consumer health - Gray zone lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123972.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


84. Lekovic D, Miljic P, Mihaljevic B: Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res; 2010 Dec;126(6):477-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma.
  • BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma, arising in the mediastinum.
  • Compression of large mediastinal vessels is common in patients with PMBCL, predisposing these patients to venous thrombosis.
  • Ten patients had a thrombosis at the moment of diagnosis PMBCL, while in five thrombosis occurred during the course of the disease.
  • Also, patients in the VTE subgroup had significantly larger diameter of mediastinal tumor mass (P=0.01) and the incidence of syndrome venae cava superior (P=0.009).
  • Use of antithrombotic prophylaxis may be considered together with chemotherapy, especially in those with bulky mediastinal tumor mass.
  • [MeSH-major] Lymphoma, B-Cell / blood. Venous Thromboembolism / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 21126629.001).
  • [ISSN] 1879-2472
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Fietz T, Knauf WU, Hänel M, Franke A, Freund M, Thiel E, East German Study Group on Hematology and Oncology-OSHO: Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. Ann Hematol; 2009 May;88(5):433-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate.
  • Primary mediastinal large B cell lymphomas (MLCL) differ from other diffuse large cell lymphomas, leading to a description as a separate entity in the current World Health Organization classification.
  • We investigated the use of a high-dose methotrexate-based alternating chemotherapy regimen (B-ALL protocol of the German ALL study group) followed by consolidative mediastinal radiotherapy first as a single-center trial, then later as a prospective multicenter trial in 44 patients with a median age of 33 years.
  • No relapse occurred more than 2 years after diagnosis and initiation of treatment, but unfortunately, no patient with overt progression or relapse within these 2 years could be salvaged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Recurrence. Survival Rate. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853160.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


86. Lanzilli G, Falchetti R, Cottarelli A, Macchi A, Ungheri D, Fuggetta MP: In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol; 2006 Jul-Sep;19(3):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study is to investigate in humans the mechanism by which the oral vaccine Polyvalent Mechanical Bacterial Lysate (PMBL) can rapidly mobilize specific immune response and evaluate the efficacy of its immunostimulating activity in preventing recurrent infections of the upper respiratory tract (URTIs) in a group of patients with a medical history of URTI recurrence.
  • The results showed that PMBL exerts a therapeutic and preventing effect in acute and recurrent infections of the upper respiratory tract and that this effect correlated with the activation and enhancement of both IgM memory B lymphocytes (CD24+/CD27+ cells) and IL2 receptor-expressing lymphocytes (CD25+ cells) involved either in humoral or cellular immunity.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. B-Lymphocytes / drug effects. Cell Extracts / pharmacology. Urinary Tract Infections / drug therapy

  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026840.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Broncho-Vaxom; 0 / Cell Extracts; 0 / Immunoglobulin M; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


87. Boulland ML, Marquet J, Molinier-Frenkel V, Möller P, Guiter C, Lasoudris F, Copie-Bergman C, Baia M, Gaulard P, Leroy K, Castellano F: Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood; 2007 Jul 1;110(1):220-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interleukin-4-induced gene 1 (IL4I1) was first described as a B-cell IL4-inducible gene and is highly expressed in primary mediastinal B-cell lymphomas.
  • Both proteins were secreted into the culture medium, and we observed the secretion of endogenous human IL4I1 (hIL4I1) protein in a mediastinal lymphoma B-cell line, MedB-1.
  • In vitro, functional enzyme was highest in mature dendritic cells (DCs), suggesting a role in antigen-presenting cell/T-lymphocyte cross-talk.
  • [MeSH-major] Amino Acid Oxidoreductases / immunology. Cell Proliferation. Dendritic Cells / chemistry. L-Amino Acid Oxidase / immunology. T-Lymphocytes / cytology
  • [MeSH-minor] Animals. Cell Line. Cell Line, Tumor. Humans. Hydrogen Peroxide / metabolism. Immunohistochemistry. Lymphoma, B-Cell / pathology. Macrophages / chemistry. Mice. Myeloid Cells / chemistry

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356132.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BBX060AN9V / Hydrogen Peroxide; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / phenylalanine oxidase; EC 1.4.3.2 / IL4I1 protein, human; EC 1.4.3.2 / L-Amino Acid Oxidase
  •  go-up   go-down


88. Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M: Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy. Intern Med; 2005 May;44(5):476-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.
  • A 56-year-old man was admitted for treatment of non-Hodgkin's lymphoma (NHL).
  • After the operation, his disease status was in partial remission (PR), and reduced-intensity allogeneic stem cell transplantation (RIST) was therefore performed for further improvement of disease status.
  • [MeSH-major] Ileostomy. Intestinal Perforation / surgery. Lymphoma, Large B-Cell, Diffuse / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Biopsy. Colon / radiography. Colon / radionuclide imaging. Colon / surgery. Follow-Up Studies. Humans. Male. Mediastinum / pathology. Mediastinum / radiography. Mediastinum / radionuclide imaging. Middle Aged. Positron-Emission Tomography. Rupture, Spontaneous. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942098.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


89. Mangasarova IaK, Magomedova AU, Kravchenko SK, Zvonkov EE, Kremenetskaia AM, Vorob'ev VI, Mar'in DS, Gubkin AV, Skidan NI, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Vorob'ev AI: [Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment]. Ter Arkh; 2010;82(7):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma with primary involvement of mediastinal lymph nodes: diagnosis and treatment].
  • AIM: To diagnose diffuse large B-cell lymphosarcoma (DLBCLS) with primary involvement of the mediastinal lymph nodes (LN) and to evaluate the efficiency of aggressive polychemotherapy (PCT).
  • There were no signs of involvement of extranodal organs at the moment of diagnosis.
  • All the 15 patients received PCT according to the modified NHL-BFM-90 program: 4 to 6 courses depending on the response to the therapy; 10 (66.6%) and 5 (33.3%) patients had 4 and 6 courses, respectively; for consolidating purpose, 11 (78.5%) patients were prescribed radiotherapy applied to the mediastinum in a cumulative dose of 36 Gy due to the fact that they had a residual mass.
  • Primary PCT resistance was confirmed in one case.
  • CONCLUSION: DLBCLS with primary LN involvement is an individual nosological entity to be differentiated from primary mediastinal large B-cell lymphosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / diagnosis. Mediastinum
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / immunology. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853612.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


90. Rózańska-Kudelska M, Maksimowicz T, Sieśkiewicz A: [B-cell lymphoma of the nose cavity--case report]. Otolaryngol Pol; 2008;62(4):496-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell lymphoma of the nose cavity--case report].
  • INTRODUCTION: Non-Hodgkin's lymphoma of the nose and sinuses accounts for 5,8-8% of the tumors in that localisation.
  • Large B-cell lymphoma (DLBCL) are frequent in mediastinum, nasopharynx, stomach and retroperitoneal space.
  • AIM: The aim of the study was to show a case of the female patient presented DLBCL-lymphoma of the right nose cavity and cutaneous lymphoma of the right lower leg.
  • MATERIAL AND METHODS: We described a case of the 68-year-old female diagnosed in Otolaryngology Clinic of the Medical University in Bialystok with DLBCL-lymphoma of the right nose cavity.
  • One month later two tumors on the skin of the right lower leg was appeared (histological: DLBCL-lymphoma).
  • CONCLUSIONS: We present the case of the rare occurrence of a DLBCL-lymphoma of the nose cavity and the skin of the lower leg.
  • Chemotherapy, immunochemotherapy and radiotherapy are suitable treatment fort that type of lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837234.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


91. Melzner I, Weniger MA, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Leithäuser F, Ritz O, Dyer MJ, Barth TF, Möller P: Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer; 2006 Apr 15;118(8):1941-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
  • We have previously shown that SOCS-1 is biallelically mutated in the primary mediastinal B-cell lymphoma (PMBL) cell line MedB-1, resulting in impaired JAK2 degradation and sustained phospho-JAK2 action.
  • SOCS-1 is frequently mutated in PMBL tumor primaries.
  • Here, we report that the PMBL cell line Karpas1106P has a biallelic deletion of the SOCS-1 region on chromosome 16p13.13.
  • In analogy to MedB-1 cells, Karpas1106P cells exhibited a retarded degradation of de novo synthesized JAK2 protein revealed by pulse/chase experiments.
  • Therefore, we conclude that loss of SOCS-1 function either by mutation or by the complete deletion of the gene plays an important role in the dysregulation of JAK/STAT signaling in Karpas1106P and PMBL.
  • [MeSH-major] Chromosomes, Human, Pair 16. Gene Deletion. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / physiology. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Repressor Proteins / physiology. Suppressor of Cytokine Signaling Proteins / genetics. Suppressor of Cytokine Signaling Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287070.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling 1 Protein; 0 / Suppressor of Cytokine Signaling Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


92. Stejskalova E, Jarosova M, Kabickova E, Smelhaus V, Mrhalova M, Kodet R: Primary mediastinal (thymic) large B-cell lymphoma with a der(14)t(8;14)(q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus. Cancer Genet Cytogenet; 2006 Oct 15;170(2):158-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal (thymic) large B-cell lymphoma with a der(14)t(8;14)(q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus.
  • We report a case of primary mediastinal (thymic) large B-cell lymphoma (PMBL) with an initial karyotype containing numerical chromosomal aberrations: +X, +9, +12, +21, and a novel translocation t(2;11)(q?31; q23 approximately 24) with a duplication of the derivative chromosome 11.
  • Our data show definitively the existence of the t(8;14) in PMBL, previously only suspected.
  • This finding supplies additional evidence that a translocation-mediated MYC activation may be an important event in the pathogenesis of this unique lymphoma.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 14. Genes, Immunoglobulin Heavy Chain. Genes, myc. Lymphoma, B-Cell / genetics. Mediastinal Neoplasms / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011988.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL: AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res; 2008 Jun 1;14(11):3338-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
  • We recently found that Reed-Sternberg cell Gal1 promotes the immunosuppressive T-helper 2/T-regulatory cell-skewed microenvironment in classical Hodgkin lymphoma (cHL).
  • In addition, because there are common signaling and survival pathways in cHL and additional non-Hodgkin lymphomas, we also evaluated whether the AP1/Gal1 signature is shared by other molecularly or morphologically related lymphomas.
  • EXPERIMENTAL DESIGN: We evaluated 225 cases of primary cHL and non-Hodgkin lymphoma for evidence of a functional AP1/Gal1 signature by immunohistochemical techniques.
  • RESULTS: Gal1 is selectively expressed by malignant Reed-Sternberg cells in >90% of primary cHLs, and Gal1 expression is concordant with the activated AP1 component, c-Jun.
  • In contrast, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and another Hodgkin-related entity, nodular lymphocyte-predominant Hodgkin lymphoma, do not express Gal1.
  • However, anaplastic large cell lymphoma (ALCL), consistently expresses both Gal1 and its transcriptional regulator, c-Jun.
  • In addition, the combination of Gal1 and c-Jun serve as diagnostic biomarkers that delineate cHL and ALCL from other lymphomas with shared morphologic and/or molecular features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 1 / biosynthesis. Hodgkin Disease / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoproliferative Disorders / metabolism. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Diagnosis, Differential. Gene Expression. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-jun / metabolism. Reed-Sternberg Cells / metabolism


94. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM: Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell; 2010 Dec 14;18(6):590-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosome band 9p24 is frequently amplified in primary mediastinal B cell lymphoma (PMBL) and Hodgkin lymphoma (HL).
  • To identify oncogenes in this amplicon, we screened an RNA interference library targeting amplicon genes and thereby identified JAK2 and the histone demethylase JMJD2C as essential genes in these lymphomas.
  • Inhibition of JAK2 and JMJD2C cooperated in killing these lymphomas by decreasing tyrosine 41 phosphorylation and increasing lysine 9 trimethylation of histone H3, promoting heterochromatin formation.
  • Hence, JAK2 and JMJD2C cooperatively remodel the PMBL and HL epigenome, offering a mechanistic rationale for the development of JAK2 and JMJD2C inhibitors in these diseases.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Cell. 2006 May 5;125(3):467-81 [16603238.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4735-9 [10987278.001]
  • [Cites] Blood. 2001 Jan 1;97(1):250-5 [11133768.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):116-20 [11242053.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):120-4 [11242054.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):561-5 [11484059.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46073-8 [12354755.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 7;301(2):287-92 [12565857.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4552-64 [15899859.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1082-4 [15815722.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] J Pathol. 2006 Mar;208(4):554-63 [16400626.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] Leukemia. 2006 Jan;20(1):157-8 [16331280.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Nature. 2006 May 4;441(7089):106-10 [16572121.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):122-30 [16737911.001]
  • [Cites] Nature. 2006 Jul 20;442(7100):307-11 [16732293.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1071-6 [16892059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9 [17093053.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):1-13 [17936700.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2545-57 [17938240.001]
  • [Cites] Adv Cancer Res. 2008;99:113-333 [18037408.001]
  • [Cites] Cell. 2008 Jan 25;132(2):259-72 [18243101.001]
  • [Cites] Cytogenet Genome Res. 2007;119(3-4):204-10 [18253030.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):489-96 [18344984.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):311-20 [18394554.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):321-30 [18394555.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):226-31 [18568025.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1790-2 [18354492.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6426-31 [18927281.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):476-87 [19136931.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):273-87 [19290934.001]
  • [Cites] Diagn Mol Pathol. 2009 Sep;18(3):144-9 [19704259.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):819-22 [19783980.001]
  • [Cites] Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5 [19858058.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4503-6 [19734449.001]
  • [Cites] Cancer Cell. 2009 Dec 8;16(6):487-97 [19962667.001]
  • [Cites] Oncogene. 2009 Dec 17;28(50):4491-500 [19784073.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1131-6 [20008298.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [CommentIn] Cancer Cell. 2010 Dec 14;18(6):539-41 [21156276.001]
  • (PMID = 21156283.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / Intramural NIH HHS / / Z01 BC011008-01; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / UO1-CA 114778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / KDM4C protein, human; EC 1.14.11.- / Jumonji Domain-Containing Histone Demethylases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ NIHMS253448; NLM/ PMC3049192
  •  go-up   go-down


95. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A; 2008 Sep 9;105(36):13520-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
  • Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL).
  • An amplicon on chromosome 19 was detected in 26% of ABC DLBCLs but in only 3% of GCB DLBCLs and PMBLs.
  • Knockdown of SPIB by RNA interference was toxic to ABC DLBCL cell lines but not to GCB DLBCL, PMBL, or myeloma cell lines, strongly implicating SPIB as an oncogene involved in the pathogenesis of ABC DLBCL.
  • Deletion of the INK4a/ARF tumor suppressor locus and trisomy 3 also occurred almost exclusively in ABC DLBCLs and was associated with inferior outcome within this subtype.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Adv Immunol. 2005;87:163-208 [16102574.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1770-7 [15886317.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7118-29 [9384589.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4487-9 [9882102.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7444-51 [15618216.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]
  • [Cites] Nature. 2006 May 4;441(7089):106-10 [16572121.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1300-3 [16673020.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] J Exp Med. 2007 Mar 19;204(3):633-43 [17353367.001]
  • [Cites] Trends Biochem Sci. 2007 Nov;32(11):509-19 [17949986.001]
  • [Cites] Science. 2008 Mar 21;319(5870):1676-9 [18323416.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1299-305 [15944719.001]
  • (PMID = 18765795.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / UO1-CA 114778; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2533222
  •  go-up   go-down


96. Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt LM, Rimsza LM: Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood; 2006 Jul 1;108(1):311-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.
  • Loss of major histocompatibility class II (MHC II) expression in diffuse large B-cell lymphoma (DLBCL) correlates with worse outcome, possibly from decreased immunosurveillance.
  • Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of DLBCL which reportedly has frequent loss of MHC II proteins; however, PM-BCL has better survival than DLBCL.